Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 10 of 110 Updated Nov 17, 2026

Cerebrolysin

FPF-1070

APPROVED IN 50+ COUNTRIES · NEUROTROPHIC PEPTIDE MIXTURE (PORCINE BRAIN)

▓ 254 indexed citations across PubMed (157), ClinicalTrials.gov (42), EuropePMC (55).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

254 citations across 9 tiers

Tap any tier to jump to that section of the bibliography.

Background

Cerebrolysin is an experimental mixture of enzymatically-treated peptides derived from pig brain whose constituents can include brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF). Although it is under preliminary study for its potential to treat various brain diseases, it is used as a therapy in dozens of countries in Eurasia.

→ Wikipedia

Mechanism of action

Mixture of low-MW peptides; neurotrophic factor-like activity on CNS neurons

Researched effects

Neurotrophic/neuroprotective; stroke/dementia/TBI benefit in trials (EU/Asia)

Reported efficacy (trial readout)

  • Stroke Recovery Rate 68%

    Cerebrolysin post-thromb (13wk)

    Medium confidence

Trial-efficacy data current as of November 16, 2026.

Live evidence

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

5-30 mL IV/IM daily for 10-20 day courses

Known concerns

Injection site reactions; headache; dizziness

Top-ranked picks

10 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. ABSTRACT NUMBER: ESOC2026A102 META-ANALYSIS: THE EFFECT OF CEREBROLYSIN COMBINED WITH SPEECH THERAPY ON NONFLUENT APHASIA RECOVERY AFTER ISCHEMIC STROKE

    2026 — META-ANALYSES · AUTHORITY 94.5

  2. Efficacy and Safety of Cerebrolysin as an Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Observational Studies.

    2026 — META-ANALYSES · AUTHORITY 94.5

  3. Post-endovascular thrombectomy perfusion imaging (CT and MR) as a prognostic biomarker and patient-selection tool for adjuvant therapy: A systematic review, meta-analysis, and clinical threshold framework.

    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2026 — META-ANALYSES · AUTHORITY 94.5

  4. Therapeutic strategies in vascular cognitive impairment: A systematic review and meta-analysis.

    2025 — META-ANALYSES · AUTHORITY 94.5

  5. [Cerebrolysin as an early add-on to reperfusion therapy: heterogeneous treatment effect analysis in ischemic stroke patients with varying risk of hemorrhagic transformation].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2024 — META-ANALYSES · AUTHORITY 94.4

  6. Comparative efficacy of neuroprotective agents for improving neurological function and prognosis in acute ischemic stroke: a network meta-analysis.

    2024 — META-ANALYSES · AUTHORITY 94.4

  7. Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis.

    Brain sciences · 2023 — META-ANALYSES · AUTHORITY 94.3

  8. Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis.

    Journal of clinical medicine · 2023 — META-ANALYSES · AUTHORITY 94.3

  9. The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review.

    Journal of Alzheimer's disease : JAD · 2022 — META-ANALYSES · AUTHORITY 94.2

  10. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021 — META-ANALYSES · AUTHORITY 94.1

Full citation library

Year distribution

Meta-Analyses

25
  1. 1.

    Ziganshina LE, Abakumova T, Vernay L · The Cochrane database of systematic reviews · 2017 · PMID 28430363

    Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from pigs' brain tissue, which has potential neuroprotective and neurotrophic properties. It is widely used in the treatment of acute ischaemic stroke in Russia, Eastern Europe, China, and other Asian and post-Soviet countries. To assess the benefits and risks of cerebrolysin for treating acute ischaemic stroke. In May 2016 we searched the Cochrane Stroke Group Trials Register, CENTRAL, MEDLINE, Embase, Web of Sci…

  2. 2.

    Cui S, Chen N, Yang M, Guo J, et al. · The Cochrane database of systematic reviews · 2019 · PMID 31710397

    Although vascular dementia is the second most common cause of dementia globally, evidence-based treatments are still lacking. Cerebrolysin is a porcine brain-derived preparation that is said to have neurotrophic and neuroprotective activity. In many parts of the world Cerebrolysin, given as a series of daily intravenous infusions, is used as a potential intervention for vascular dementia. A previous Cochrane Review on Cerebrolysin in vascular dementia yielded inconsistent results. We wished to u…

  3. 3.

    Ziganshina LE, Abakumova T, Hoyle CH · The Cochrane database of systematic reviews · 2020 · PMID 32662068

    Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from porcine brain that has potential neuroprotective properties. It is widely used in the treatment of acute ischaemic stroke in Russia, Eastern Europe, China, and other Asian and post-Soviet countries. This is an update of a review first published in 2010 and last updated in 2017. To assess the benefits and harms of Cerebrolysin for treating acute ischaemic stroke. We searched the Cochrane Stroke Group Trials Re…

  4. 4.

    Chen N, Yang M, Guo J, Zhou M, et al. · The Cochrane database of systematic reviews · 2013 · PMID 23440834

    Vascular dementia is a common disorder without definitive treatments. Cerebrolysin seems to be a promising intervention based on its potential neurotrophic and pro-cognitive effects, but studies of its efficacy have yielded inconsistent results. To assess the efficacy and safety of Cerebrolysin for vascular dementia. We searched ALOIS - the Cochrane Dementia and Cognitive Improvement Group's Specialized Register on 4 November 2012 using the terms: Cerebrolysin, Cere, FPF1070, FPF-1070. ALOIS con…

  5. 5.

    Li M, Huo X, Chang Q, Liu X, et al. · Frontiers in pharmacology · 2024 · PMID 39575393

    This network meta-analysis aims to explore the efficacy and safety of neuroprotective agents in patients with ischemic stroke and attempts to identify which drug is the most effective in improving outcomes for patients with acute ischemic stroke (AIS) through a ranking method. We comprehensively searched the PubMed, Medline, Embase, Web of Science, and Cochrane library databases from their establishment to 30 June 2024. Data were extracted from the studies identified, and their quality was asses…

  6. 6.

    Ziganshina LE, Abakumova T, Vernay L · The Cochrane database of systematic reviews · 2016 · PMID 27918088

    Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from pigs' brain tissue, which has potential neuroprotective and neurotrophic properties. It is widely used in the treatment of acute ischaemic stroke in Russia, Eastern Europe, China, and other Asian and post-Soviet countries. To assess the benefits and risks of cerebrolysin for treating acute ischaemic stroke. In May 2016 we searched the Cochrane Stroke Group Trials Register, CENTRAL, MEDLINE, Embase, Web of Sci…

  7. 7.

    Jarosz K, Kojder K, Andrzejewska A, Solek-Pastuszka J, et al. · Brain sciences · 2023 · PMID 36979317

    TBI (traumatic brain injury) is one of the most common causes of deaths and failure to return to society according to the latest statistics. Cerebrolysin is a drug approved for use in patients diagnosed with TBI. It is a mixture of neuropeptides derived from purified porcine brain proteins and multiple experimental studies have proven its neuroprotective and neurorestorative properties both in vitro and in vivo. In our meta-analysis, we analyze the latest clinical study reports on the use of Cer…

  8. 8.

    Kojder K, Jarosz K, Bosiacki M, Andrzejewska A, et al. · Journal of clinical medicine · 2023 · PMID 37892776

    Subarachnoid Hemorrhage (SAH) is one of the acute neurological conditions that is associated with high mortality and recovery failure rates. In recent years, due to the development of endovascular and classical techniques, the mortality rate after SAH has decreased. Currently, more research is focused on understanding the molecular mechanisms underlying SAH. Methods of treatment are investigated in order to obtain the best treatment result, not only survival. One of the drugs used in stroke, inc…

  9. 9.

    Fan F, Liu H, Shi X, Ai Y, et al. · Journal of Alzheimer's disease : JAD · 2022 · PMID 34924395

    Evidence summaries for efficacy and safety of frequently employed treatments of Alzheimer's disease (AD) are sparse. We aimed to perform an updated umbrella review to identify an efficacious and safe treatment for AD patients. We conducted a search for meta-analyses and systematic reviews on the Embase, PubMed, The Cochrane Library, and Web of Science to address this knowledge gap. We examined the cognitive functions, behavioral symptoms, global clinical assessment, and Activities of Daily Livin…

  10. 10.

    Gauthier S, Proaño JV, Jia J, Froelich L, et al. · Dementia and geriatric cognitive disorders · 2015 · PMID 25832905

    The aim of this study was to provide a systematic and quantitative summary of benefit and risk of Cerebrolysin in patients with mild-to-moderate Alzheimer's disease (AD) and to avoid major deficiencies of an earlier meta-analysis. This is a meta-analysis of randomized double-blind placebo-controlled clinical trials. Trials were identified with the help of PubMed, the Cochrane Dementia Group database, the Center for Collaborative Neurosciences, and references from reviews; no language restriction…

  11. 11.

    Vester JC, Buzoianu AD, Florian SI, Hömberg V, et al. · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021 · PMID 33620612

    This prospective meta-analysis summarizes results from the CAPTAIN trial series, evaluating the effects of Cerebrolysin for moderate-severe traumatic brain injury, as an add-on to usual care. The study included two phase IIIb/IV prospective, randomized, double-blind, placebo-controlled clinical trials. Eligible patients with a Glasgow Coma Score (GCS) between 6 and 12 received study medication (50 mL of Cerebrolysin or physiological saline solution per day for ten days, followed by two additiona…

  12. 12.

    Zhang D, Dong Y, Li Y, Chen J, et al. · BioMed research international · 2017 · PMID 28656143

    Cerebrolysin was reported to be effective in the neurological improvement of patients with acute ischemic stroke (AIS) in experimental models, while data from clinical trials were inconsistent. We performed a meta-analysis to explore the efficacy and safety of cerebrolysin for AIS. PubMed, EMBASE, and Cochrane Library were searched for randomized controlled trials, which intervened within 72 hours after the stroke onset. We investigated the efficacy and safety outcomes, respectively. Risk ratios…

  13. 13.

    Wei ZH, He QB, Wang H, Su BH, et al. · Journal of neural transmission (Vienna, Austria : 1996) · 2007 · PMID 17318304

    To determine the therapeutic effect of nootropic agent Cerebrolysin on patients with mild to moderate Alzheimer's disease (AD), we searched the Cochrane Library, Medline, PubMed, and Chinese Biomedical Literature Analysis and Retrieval System for Compact Disc (CBMDISC), and communicated with EBEWE Pharmaceutical Ltd, for randomized trials comparing Cerebrolysin with placebo in AD. Available data on clinical global impression, cognitive performance and activities of daily living were extracted fr…

  14. 14.

    Wang Z, Shi L, Xu S, Zhang J · Drug design, development and therapy · 2017 · PMID 28458521

    Cerebrolysin has been shown to have an inconsistent efficacy on functional recovery in patients with acute ischemic stroke (AIS). The present meta-analysis aims to evaluate the value of cerebrolysin and to explore the potential influencing factors. The main electronic databases, including MEDLINE, EMBASE, and the Cochrane Library, were searched. The primary outcome was functional recovery at Day 90. The secondary outcomes included mortality and adverse events. A total of 1,649 patients with AIS…

  15. 15.

    El Sayed I, Zaki A, Fayed AM, Shehata GM, et al. · Neurosurgical review · 2018 · PMID 27539610

    Traumatic brain injury is a major problem worldwide. Our objective is to synthesize available evidence in the literature concerning the effectiveness of neuroprotective drugs (cerebrolysin, citicoline, and piracetam) on Glasgow outcome score (GOS), cognitive performance, and survival in traumatic brain injury patients. Comprehensive search of electronic databases, search engines, and conferences proceedings; hand search journals; searching reference lists of relevant articles, theses, and local…

  16. 16.

    Strilciuc S, Vécsei L, Boering D, Pražnikar A, et al. · Pharmaceuticals (Basel, Switzerland) · 2021 · PMID 34959697

    We performed a systematic search and meta-analysis of available literature to determine the safety profile of Cerebrolysin in acute ischemic stroke, filling existing safety information gaps and inconsistent results. We searched EMBASE, PubMed, and Cochrane Databases of Systematic Reviews and Clinical Trials up to the end of February 2021. Data collection and analysis were conducted using methods described in the Cochrane Handbook for Systematic Reviews of Interventions. All safety outcomes were…

  17. 17.

    Kalinin MN, Khasanova DR · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2024 · PMID 38512096

    The study goal was the assessment of heterogeneous treatment effects of Cerebrolysin as an early add-on to reperfusion therapy in stroke patients with varying risk of hemorrhagic transformation (HT). It was post hoc analysis of the CEREHETIS trial (ISRCTN87656744). Patients with middle cerebral artery infarction ( Heterogeneity of Cerebrolysin treatment effects was moderate (I Clinically meaningful heterogeneity of Cerebrolysin treatment effects on HT and functional outcome was established in st…

  18. 18.

    Guekht A, Vester J, Heiss WD, Gusev E, et al. · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017 · PMID 28707130

    This meta-analysis combines the results of two identical stroke studies (CARS-1 and CARS-2) assessing efficacy of Cerebrolysin on motor recovery during early rehabilitation. Cerebrolysin is a parenterally administered neuropeptide preparation approved for the treatment of stroke. Both studies had a prospective, randomized, double-blind, placebo-controlled design. Treatment with 30 ml Cerebrolysin once daily for 3 weeks was started 24-72 h after stroke onset. In addition, patients participated in…

  19. 19.

    Bornstein NM, Guekht A, Vester J, Heiss WD, et al. · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2018 · PMID 29248999

    This meta-analysis combines the results of nine ischemic stroke trials, assessing efficacy of Cerebrolysin on global neurological improvement during early post-stroke period. Cerebrolysin is a parenterally administered neuropeptide preparation approved for treatment of stroke. All included studies had a prospective, randomized, double-blind, placebo-controlled design. The patients were treated with 30-50 ml Cerebrolysin once daily for 10-21 days, with treatment initiation within 72 h after onset…

  20. 20.

    Patel PN, Mangal D, Patel K · Cureus · 2025 · PMID 41018475

    Cerebrolysin, a neurotrophic compound, has been investigated as a neurorestorative therapy in acute ischemic stroke, although findings are inconsistent due to limitations in study inclusion and outcome reporting. This systematic review and meta-analysis evaluated the efficacy and safety of Cerebrolysin in improving neurological and functional outcomes following acute ischemic stroke. Fourteen randomized controlled trials (N = 2,884 patients) comparing Cerebrolysin to placebo were included. The p…

  21. 21.
  22. 22.

    Afridi A, Sajjad F, Arshad A, Shahid I, Fatima NE, Alam U, Hoti RK, Abdullah M, Khan S, GhanimAl-Badri S, Khan S, Bakkar MA, Saeed A, Ali A, Khan LA, Kamil KA. · 2026 · PMID 41880098

    <h4>Background</h4>One of the primary causes of morbidity and death is still acute ischemic stroke (AIS). Although mechanical thrombectomy (MT) yields better results, problems such as partial functional recovery persist. By lessening secondary damage and encouraging recovery, the neuroprotective drug, cerebrolysin, may improve the effectiveness of MT. Its safety and efficacy as an adjunct to MT are assessed in this study.<h4>Methods</h4>PubMed, Embase, and Cochrane databases were systematically…

  23. 23.

    Wang Y, Li M, Jiang Y, Ji Q. · 2024 · PMID 39834702

    <h4>Background</h4>Ischemic stroke is the second leading cause of death and the third leading cause of combined disability and mortality globally. While reperfusion therapies play a critical role in the management of acute ischemic stroke (AIS), their applicability is limited, leaving many patients with significant neurological deficits and poor prognoses. Neuroprotective agents have garnered attention for their potential as adjunct therapies; however, their relative efficacy remains unclear. Th…

  24. 24.

    Masserini F, Gendarini C, Baso G, Salvadori E, Pantoni L. · 2025 · PMID 41198594

    <h4>Introduction</h4>Vascular cognitive impairment (VCI) is a common, heterogeneous condition, currently lacking approved treatments.<h4>Methods</h4>We reviewed therapeutic strategies tested in VCI and meta-analyzed efficacy data for eligible interventions to assess whether previously tested treatments warranted reconsideration.<h4>Results</h4>One-hundred seventy-three trials were extracted (22,347 participants, four VCI categories, 91 interventions, 145 outcomes). Ginkgo biloba extracts showed…

  25. 25.

    Eichel R, Teitcher M, Mausbach S, Poplavska A, et al. · Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2026 · PMID 42607786

    Despite high rates of macrovascular recanalization, approximately half of patients with large vessel occlusion stroke fail to achieve functional independence after endovascular thrombectomy (EVT). Residual tissue-level perfusion abnormalities - detectable on post-procedural CT perfusion (CTP) - have been proposed as a biomarker of futile recanalization. We aimed to establish post-EVT perfusion imaging (by CT or MR perfusion) as a surrogate marker predictive of functional independence on the modi…

Systematic Reviews

4
  1. 26.

    Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K · The Cochrane database of systematic reviews · 2023 · PMID 37818733

    Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from porcine brain, which has potential neuroprotective properties. It is widely used in the treatment of acute ischaemic stroke in Russia, Eastern Europe, China, and other Asian and post-Soviet countries. This is an update of a review first published in 2010 and last updated in 2020. To assess the benefits and harms of Cerebrolysin or Cerebrolysin-like agents for treating acute ischaemic stroke. We searched the C…

  2. 27.

    Ziganshina LE, Abakumova T · The Cochrane database of systematic reviews · 2015 · PMID 26083192

    Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from pigs' brain tissue, which has potential neuroprotective and neurotrophic properties. It is widely used in the treatment of acute ischaemic stroke in Russia, China, and other Asian and post-Soviet countries. To assess the benefits and risks of Cerebrolysin for treating acute ischaemic stroke. We searched the Cochrane Stroke Group Trials Register (October 2014), the Cochrane Central Register of Controlled Trial…

  3. 28.

    Ziganshina LE, Abakumova T, Kuchaeva A · The Cochrane database of systematic reviews · 2010 · PMID 20393954

    Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from pigs' brain tissue which has proposed neuroprotective and neurotrophic properties. It is widely used in the treatment of acute ischaemic stroke in Russia and China. To assess the benefits and risks of cerebrolysin for treating acute ischaemic stroke. We searched the Cochrane Stroke Group Trials Register (February 2009), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1…

  4. 29.

    Hassan BD, Dabas MM, Kanemitsu K, Faran N, et al. · Cureus · 2024 · PMID 39534815

    This systematic review evaluates the effectiveness of various neuroprotective strategies in enhancing recovery following acute ischemic stroke, focusing on interventions such as normobaric oxygen (NBO), lithium, selective serotonin reuptake inhibitors (SSRIs), and Cerebrolysin. Drawing upon data from six primary studies, including randomized controlled trials (RCTs) and meta-analyses, we assessed these therapies' impact on functional outcomes, motor recovery, and neurological improvement. Normob…

Randomised Controlled Trials

12
  1. 30.

    Homberg V, Jianu DC, Stan A, Strilciuc Ș, et al. · Stroke · 2025 · PMID 39957612

    Stroke-induced aphasia significantly impacts communication and quality of life. Despite the standard treatment being speech and language therapy, outcomes vary, highlighting the need for additional therapies. Cerebrolysin, a neuroprotective and neurotrophic agent, has shown potential in stroke management. This study addresses the notable gap in research about the combined use of Cerebrolysin and speech therapy, evaluating their synergistic potential in the treatment of aphasia. The ESCAS trial (…

  2. 31.

    Firstenfeld AJ, Listorti J, Jalaff N, Loaiza Orozco CP, et al. · Journal of medicine and life · 2023 · PMID 38585517

    Amyotrophic lateral sclerosis (ALS) is a devastating and progressive neurodegenerative disease with limited treatment options available. Cerebrolysin is a drug candidate for the treatment of ALS because of its neuroprotective and neuroregenerative effects. We initiated a pilot clinical study of a combination of Cerebrolysin and riluzole to assess the therapeutic benefit of Cerebrolysin as an add-on treatment on clinical signs and symptoms in outpatients with ALS. Twenty patients with a clinicall…

  3. 32.

    Poon W, Matula C, Vos PE, Muresanu DF, et al. · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020 · PMID 31494820

    To evaluate the safety and efficacy of Cerebrolysin as an add-on therapy to local standard treatment protocol in patients after moderate-to-severe traumatic brain injury. The patients received the study medication in addition to standard care (50 mL of Cerebrolysin or physiological saline solution daily for 10 days, followed by two additional treatment cycles with 10 mL daily for 10 days) in a prospective, randomized, double-blind, placebo-controlled, parallel-group, multi-centre phase IIIb/IV t…

  4. 33.

    Chang WH, Park CH, Kim DY, Shin YI, et al. · BMC neurology · 2016 · PMID 26934986

    Cerebrolysin is a neuropeptide preparation with neuroprotective and neurorestorative effects. Combining Cerebrolysin treatment with a standardized rehabilitation program may have a potential synergistic effect in the subacute stage of stroke. This study aims to evaluate whether Cerebrolysin provides additional motor recovery on top of rehabilitation therapy in the subacute stroke patients with moderate to severe motor impairment. This phase IV trial was designed as a prospective, multicenter, ra…

  5. 34.

    Khasanova DR, Kalinin MN · BMC neurology · 2023 · PMID 36973684

    Cerebrolysin could mitigate reperfusion injury and hemorrhagic transformation (HT) in animal models of acute ischemic stroke. This was a prospective, randomized, open-label, parallel-group with active control, multicenter pilot study. Cerebrolysin (30 mL/day over 14 days) was administered concurrently with alteplase (0.9 mg/kg) in 126 patients, whereas 215 control patients received alteplase alone. The primary outcomes were the rate of any and symptomatic HT assessed from day 0 to 14. The second…

  6. 35.

    Samir A, Nasef N, Fathy K, El-Gilany AH, et al. · Journal of neonatal-perinatal medicine · 2022 · PMID 33935111

    A significant proportion of preterm infants experience developmental delay despite receiving a post discharge early interventional care. Cerebrolysin is a peptide mixture which acts similar to endogenous neurotrophic factors through promoting neurogenesis and enhancing neuronal plasticity. To compare the effect of Cerebrolysin plus routine intervention program versus routine intervention program alone on the outcome of preterm infants at high risk for neurodevelopmental delay. In a randomized co…

  7. 36.

    Mitrović SZ, Konstantinović LM, Miler Jerković V, Dedijer-Dujović S, et al. · Medicina (Kaunas, Lithuania) · 2023 · PMID 36837492

  8. 37.

    Muresanu DF, Heiss WD, Hoemberg V, Bajenaru O, et al. · Stroke · 2016 · PMID 26564102

    The aim of this trial was to investigate whether stroke patients who receive Cerebrolysin show improved motor function in the upper extremities at day 90 compared with patients who receive a placebo. This study was a prospective, randomized, double-blind, placebo-controlled, multicenter, parallel-group study. Patients were treated with Cerebrolysin (30 mL/d) or a placebo (saline) once daily for 21 days, beginning at 24 to 72 hours after stroke onset. The patients also participated in a standardi…

  9. 38.

    Xiao S, Xue H, Li G, Yuan C, et al. · The Australian and New Zealand journal of psychiatry · 2012 · PMID 22311531

    Cerebrolysin is a nootropic drug with unique neurotrophic activities directly affecting cerebral neurons. This study evaluated the efficacy and safety of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms. The trial was a double-blind, placebo-controlled, parallel-group design. A total of 109 patients who met the DSM-IV diagnostic criteria for schizophrenia were randomly assigned to cerebrolysin (cerebrolysin plus risperidone, n=55) or placebo (risper…

  10. 39.

    Alvarez XA, Winston CN, Barlow JW, Sarsoza FM, et al. · Journal of Alzheimer's disease : JAD · 2022 · PMID 36155516

    Plasma neuronal-derived extracellular vesicles (NDEV) contain proteins of pathological, diagnostic, and therapeutic relevance. We investigated the associations of six plasma NDEV markers with Alzheimer's disease (AD) severity, cognition and functioning, and changes in these biomarkers after Cerebrolysin®, donepezil, and a combination therapy in AD. Plasma NDEV levels of Aβ42, total tau, P-T181-tau, P-S393-tau, neurogranin, and REST were determined in: 1) 116 mild to advanced AD patients and in 2…

  11. 40.

    Ponomareva EV, Androsova LV, Krynskiy SA, Gavrilova SI · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2024 · PMID 39435777

    To study the efficacy and safety of long-term (3 years) course Cerebrolysin therapy in an open comparative study as a means potentially capable of slowing or preventing the transition of MCI into dementia, as well as to analyze the possibility of Cerebrolysin preventive effect predicting based on clinical and biological parameters. In total, 100 patients with aMCI were included in the study, randomly assigned to 2 groups: patients of group 1 ( A comparative three-year prospective study conducted…

  12. 41.

    Zhang L, Chopp M, Lu M, Zhang T, et al. · International journal of stroke : official journal of the International Stroke Society · 2017 · PMID 28382851

    Background and aims In an effort to characterize the effects of Cerebrolysin for treatment of stroke that are essential for successful clinical translation, we have demonstrated that Cerebrolysin dose dependently enhanced neurological functional recovery in experimental stroke. Here, we conduct a prospective, randomized, placebo-controlled, blinded study to examine the therapeutic window of Cerebrolysin treatment of rats subjected to embolic stroke. Methods Male Wistar rats age 3-4 months (n = 1…

Clinical Trials

1
  1. 42.

    Staszewski J, Dębiec A, Strilciuc S, Gniadek-Olejniczak K, et al. · Translational stroke research · 2025 · PMID 40325343

    This study hypothesized that Cerebrolysin, a multimodal neuroprotective agent, enhances the efficacy and safety of mechanical thrombectomy (MT) in both acute ischemic stroke (AIS) and recovery stroke phases in selected patients with good collateral status (CTA-CS 2-3) and effective recanalization (mTICI 2b-3). A single-center, prospective, open-label, single-arm study with blinded outcome assessment of 50 consecutive patients with moderate-to-severe AIS treated with MT ≤ 6 h of stroke onset foll…

Trial Registrations (ClinicalTrials.gov)

42
  1. 43.

    NCT03506841 · Phase 1 · Completed · 2016

    Conditions: Infant Development, Cerebral Palsy, Preterm Infant

  2. 44.

    NCT06208540 · Phase 4 · Completed · 2021

    Conditions: Post-covid-19 Persistent Smell and Taste Disorders

  3. 45.

    NCT04830943 · Phase 3 · Completed · 2020

    Conditions: Covid19 Related Anosmia and Aguesia

  4. 46.

    NCT01059461 · Phase 2 · Completed · 2011

    Conditions: Hypoxic-Ischemic Encephalopathy

  5. 47.

    NCT05755997 · Phase 2 · Active Not Recruiting · 2023

    Conditions: Cadasil

  6. 48.

    NCT01822951 · Phase 4 · Withdrawn

    Conditions: Alzheimer Disease

  7. 49.

    NCT06429943 · Completed · 2021

    Conditions: SAH (Subarachnoid Hemorrhage)

  8. 50.

    NCT06899464 · Phase 4 · Not Yet Recruiting · 2025

    Conditions: Intracerebral Hemorrhage, Hemorrhagic Stroke, Intracerebral, Hemorrhagic Stroke (+1)

  9. 51.

    NCT06273020 · Phase 4 · Unknown · 2022

    Conditions: Ischemic Stroke, Acute, Diabetes Mellitus, Type 2, Blood Brain Barrier

  10. 52.

    NCT05124353 · Phase 2/Phase 3 · Unknown · 2021

    Conditions: Stroke, Acute, Ischemic

  11. 53.

    NCT02149875 · Phase 1/Phase 2 · Completed · 2010

    Conditions: Acute Cerebral Stroke Within 12 Hours for the First Time

  12. 54.

    NCT06677502 · NA · Enrolling By Invitation · 2024

    Conditions: Cognitive Impairment

  13. 55.

    NCT05821075 · Phase 1/Phase 2 · Recruiting · 2023

    Conditions: Bell Palsy

  14. 56.

    NCT02541227 · Terminated · 2014

    Conditions: Ischemic Stroke

  15. 57.
  16. 58.

    NCT05807503 · Completed · 2020

    Conditions: TBI (Traumatic Brain Injury)

  17. 59.

    NCT07043686 · NA · Recruiting · 2025

    Conditions: Ischemic Stroke, Acute, Rehabilitation Outcome, Cerebrolysin

  18. 60.

    NCT03480698 · Completed · 2018

    Conditions: Acute Ischemic Stroke

  19. 61.

    NCT01787123 · Phase 2/Phase 3 · Completed · 2013

    Conditions: Subarachnoid Hemorrhage, Intracranial Aneurysm, Delayed Cerebral Ischemia (+1)

  20. 62.

    NCT05288465 · NA · Completed · 2014

    Conditions: Hair Problems

  21. 63.

    NCT00840671 · Phase 3 · Completed · 2005

    Conditions: Stroke

  22. 64.

    NCT02116348 · Phase 2 · Unknown · 2014

    Conditions: Cerebral Palsy Children, Children With Traumatic Brain Injury, Mental Handicap (+1)

  23. 65.

    NCT00868283 · Phase 4 · Completed · 2006

    Conditions: Ischemic Stroke

  24. 66.

    NCT04427241 · Phase 4 · Recruiting · 2023

    Conditions: Disorder of Consciousness, Hemorrhagic Stroke

  25. 67.

    NCT04904341 · Phase 3 · Unknown · 2021

    Conditions: Stroke, Ischemic, Stroke, Acute, Stroke Sequelae

  26. 68.
  27. 69.

    NCT06052787 · Phase 3 · Completed · 2023

    Conditions: Traumatic Brain Injury

  28. 70.

    NCT04124367 · Phase 2 · Terminated · 2021

    Conditions: Chronic Stroke, Subacute Stroke

  29. 71.

    NCT05864677 · NA · Unknown · 2023

    Conditions: Neurocognitive Disorders, Surgery-Complications, Critical Illness (+2)

  30. 72.

    NCT06489925 · EARLY_Phase 1 · Not Yet Recruiting · 2024

    Conditions: Basilar Artery Occlusion, Posterior Circulation Brain Infarction

  31. 73.
  32. 74.

    NCT00947531 · Phase 4 · Completed · 2006

    Conditions: Vascular Dementia

  33. 75.

    NCT01606111 · Phase 4 · Terminated · 2013

    Conditions: Traumatic Brain Injury

  34. 76.

    NCT02768571 · Phase 4 · Completed · 2016

    Conditions: Stroke

  35. 77.
  36. 78.

    NCT00911807 · Phase 2 · Completed · 2004

    Conditions: Alzheimer Disease

  37. 79.

    NCT06339411 · Phase 2 · Not Yet Recruiting · 2024

    Conditions: Acute Ischemic Stroke

  38. 80.

    NCT02581371 · Phase 4 · Unknown · 2015

    Conditions: Ischemic Stroke

  39. 81.

    NCT06078215 · Phase 4 · Unknown · 2023

    Conditions: Acute Ischemic Stroke

  40. 82.

    NCT01996761 · Phase 4 · Completed · 2011

    Conditions: Cerebrolysin

  41. 83.

    NCT04751136 · Phase 2 · Completed · 2016

    Conditions: Down Syndrome

  42. 84.

    NCT07846488 · NA · Not Yet Recruiting · 2026

    Conditions: Ischemic Stroke, Hemiplegia, Neurogenic Dysphagia

Reviews

37
  1. 85.

    Yanık T, Yanık B · Turkish journal of physical medicine and rehabilitation · 2024 · PMID 38948647

    What is expected from neuroprotection is to inhibit neuronal death and halt or decelerate the neuronal loss to lower the mortality rates, decrease disability, and improve the quality of life following an acute ischemic stroke. Several agents were described as neuroprotective up to date; however, there is still debate which to use in the neurorehabilitation of stroke patients, in terms of both efficacy and also safety. In this review, we discuss the agents, citicoline, cerebrolysin and MLC901 (Ne…

  2. 86.

    Plosker GL, Gauthier S · Drugs & aging · 2009 · PMID 19848437

    Cerebrolysin is a parenterally administered, porcine brain-derived peptide preparation that has pharmacodynamic properties similar to those of endogenous neurotrophic factors. In several randomized, double-blind trials of up to 28 weeks' duration in patients with Alzheimer's disease, Cerebrolysin was superior to placebo in improving global outcome measures and cognitive ability. A large, randomized comparison of Cerebrolysin, donepezil or combination therapy showed beneficial effects on global m…

  3. 87.

    Brainin M · Expert review of neurotherapeutics · 2018 · PMID 30004268

    Cerebrolysin is a neuropeptide preparation with neurotrophic effects and promotes recovery after brain injury. Its preclinical profile promises wide applications due to its multi-target effects. Currently, Cerebrolysin is used for treatment of cerebral ischemia and neurodegeneration. Areas covered: In stroke, earlier clinical trials with Cerebrolysin were performed mostly in mildly affected stroke populations, which usually have a favorable prognosis. Due to this selection, a floor or ceiling ef…

  4. 88.

    iganshina LE, Abakumova TR · Vestnik Rossiiskoi akademii meditsinskikh nauk · 2013 · PMID 23805635

    The review discusses existing evidence of benefits and risks of cerebrolysin--a mixture of low-molecular-weight peptides and amino acids derived from pigs' brain tissue with proposed neuroprotective and neurotrophic properties, for acute ischemic stroke. The review presents results of systematic search and analysis of randomised clinical trials comparing cerebrolysin with placebo in patients with acute ischemic stroke. Only one trial was selected as meeting quality criteria. No difference in dea…

  5. 89.

    Thome J, Doppler E · Drugs of today (Barcelona, Spain : 1998) · 2012 · PMID 22514795

    The safety of Cerebrolysin has been shown through many years of clinical use, observations from postmarketing surveillance studies, and safety data from randomized, controlled clinical trials. The reported events showed that adverse reactions to Cerebrolysin were generally mild and transient. Most common adverse events included vertigo, agitation and feeling hot. In the controlled clinical trials analyzed for this report, the incidence of adverse events was similar in Cerebrolysin- and placebo-t…

  6. 90.

    Ozkizilcik A, Sharma A, Lafuente JV, Muresanu DF, et al. · Progress in brain research · 2019 · PMID 30961868

    Parkinson's disease (PD) is affecting >10 million people worldwide for which no suitable cure has been developed so far. Roughly, about two people per thousand populations are affected with PD like symptoms especially over the age of 50. About 1% of the populations above 60 years suffer from PD-like disease. The prevalence of the disease is increasing over the years, and future projections by 2020 could be 12-14 millions people affected by the disease. Thus, exploration of suitable therapeutic m…

  7. 91.

    Fiani B, Covarrubias C, Wong A, Doan T, et al. · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021 · PMID 33515100

    Cerebrolysin therapy has the potential to significantly aid in the treatment of a wide variety of debilitating neurological diseases including ischemic strokes, neurodegenerative disorders, and traumatic brain injuries. Although Cerebrolysin is not approved for use in the USA, it is used clinically in over 50 countries worldwide. In this review, we focus on outlining the role that Cerebrolysin has in stimulating the molecular signaling pathways that are critical for neurological regeneration and…

  8. 92.

    Ozkizilcik A, Sharma A, Feng L, Muresanu DF, et al. · International review of neurobiology · 2023 · PMID 37783564

    Concussive head injury (CHI) is one of the major risk factors for developing Parkinson's disease in later life of military personnel affecting lifetime functional and cognitive disturbances. Till date no suitable therapies are available to attenuate CHI or PD induced brain pathology. Thus, further exploration of novel therapeutic agents are highly warranted using nanomedicine in enhancing the quality of life of veterans or service members of US military. Since PD or CHI induces oxidative stress…

  9. 93.

    Mureșanu DF, Livinț Popa L, Chira D, Dăbală V, et al. · Journal of clinical medicine · 2022 · PMID 35268364

    Stroke is still a significant health problem that affects millions of people worldwide, as it is the second-leading cause of death and the third-leading cause of disability. Many changes have occurred in the treatment of acute ischemic stroke. Although the innovative concepts of neuroprotection and neurorecovery have been vigorously investigated in a substantial number of clinical studies in the past, only a few trials managed to increase the number of promising outcomes with regard to the multi…

  10. 94.

    Flores G, Flores-Gómez GD, Díaz A, Penagos-Corzo JC, et al. · Synapse (New York, N.Y.) · 2020 · PMID 32779216

    Aging is a complex process that can lead to neurodegeneration and, consequently, several pathologies, including dementia. Physiological aging leads to changes in several body organs, including those of the central nervous system (CNS). Morphological changes in the CNS and particularly the brain result in motor and cognitive deficits affecting learning and memory and the circadian cycle. Characterizing neural modifications is critical to designing new therapies to target aging and associated path…

  11. 95.

    Allegri RF, Guekht A · Drugs of today (Barcelona, Spain : 1998) · 2012 · PMID 22514793

    Dementia is the result of various cerebral disorders, leading to an acquired loss of memory and impaired cognitive ability. The most common forms are Alzheimer's disease (AD) and vascular dementia (VaD). Neurotrophic factors are essential for the survival and differentiation of developing neurons and protecting them against damage under pathologic conditions. Cerebrolysin is a peptide preparation that mimics the pleiotropic effects of neurotrophic factors. Several clinical trials investigating t…

  12. 96.

    Sharma HS, Muresanu DF, Castellani RJ, Nozari A, et al. · Progress in brain research · 2019 · PMID 30961867

    Alzheimer's disease (AD) is estimated to be afflicting over 55 millions of individual worldwide in 2018-19 for which no suitable clinical therapeutic measures have been developed so far. Thus, there is an urgent need to explore novel therapeutic strategies using nanodelivery of drugs and agents either alone or in combination for superior neuroprotection in AD and enhanced quality of life of the affected individuals. There are reports that AD is often associated with diminished neurotrophic facto…

  13. 97.

    Dalrymple-Alford JC, Harland B, Loukavenko EA, Perry B, et al. · Neuroscience and biobehavioral reviews · 2015 · PMID 25637779

    Injury to the anterior thalamic nuclei (ATN) and their neural connections is the most consistent neuropathology associated with diencephalic amnesia. ATN lesions in rats produce memory impairments that support a key role for this region within an extended hippocampal system of complex overlapping neural connections. Environmental enrichment is a therapeutic tool that produces substantial, although incomplete, recovery of memory function after ATN lesions, even after the lesion-induced deficit ha…

  14. 98.

    Fiani B, Chacon D, Jarrah R, Barthelmass M, et al. · Acta neurologica Belgica · 2021 · PMID 34494216

    Perinatal asphyxia (PA) is a devastating neonatal condition characterized by a lack of oxygen supporting the organ systems. PA can lead to hypoxic-ischemic encephalopathy (HIE), a brain dysfunction due to oxygen deprivation with a complex neurological sequela. The pathophysiology of HIE and PA is not entirely understood, with therapeutic hypothermia being the standard treatment with only limited value. However, alternative neuroprotective therapies can be a potential treatment modality. In this…

  15. 99.

    Wan M, Yang K, Zhang G, Yang C, et al. · Medicine · 2024 · PMID 38552072

    This study conducts a rapid health technology assessment to systematically evaluate the effectiveness, safety, and cost-effectiveness of Cerebrolysin as an adjunctive therapy for acute ischemic stroke to provide evidence-based medicine for clinical decisions of Cerebrolysin. All systematic reviews/meta-analyses, pharmacoeconomic studies, and health technology assessment reports of Cerebrolysin for the treatment of acute ischemic stroke before August 17, 2023, were retrieved from PubMed, Embase,…

  16. 100.

    Rejdak K, Sienkiewicz-Jarosz H, Bienkowski P, Alvarez A · Medicinal research reviews · 2023 · PMID 37052231

    Neurotrophic factors (NTFs) are involved in the pathophysiology of neurological disorders such as dementia, stroke and traumatic brain injury (TBI), and constitute molecular targets of high interest for the therapy of these pathologies. In this review we provide an overview of current knowledge of the definition, discovery and mode of action of five NTFs, nerve growth factor, insulin-like growth factor 1, brain derived NTF, vascular endothelial growth factor and tumor necrosis factor alpha; as w…

  17. 101.

    Sharma HS, Muresanu DF, Nozari A, Lafuente JV, et al. · Advances in neurobiology · 2023 · PMID 37480461

    Concussive head injury (CHI) is one of the major risk factors in developing Alzheimer's disease (AD) in military personnel at later stages of life. Breakdown of the blood-brain barrier (BBB) in CHI leads to extravasation of plasma amyloid beta protein (ΑβP) into the brain fluid compartments precipitating AD brain pathology. Oxidative stress in CHI or AD is likely to enhance production of nitric oxide indicating a role of its synthesizing enzyme neuronal nitric oxide synthase (NOS) in brain patho…

  18. 102.

    Bogolepova AN · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2026 · PMID 42054336

    Stroke remains a leading cause of disability worldwide. Cognitive impairment is a major consequence, with post-stroke aphasia developing in approximately 30% of patients after a first stroke. Speech impairments substantially reduce quality of life, complicate rehabilitation, and hinder reintegration into daily activities. Patients with aphasia exhibit greater cognitive deficits and an increased risk of vascular dementia, regardless of stroke type. Speech therapy is a primary treatment modality.…

  19. 103.

    Zakharov VV, Vakhnina NV, Gogoleva AG · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2021 · PMID 34037360

    The narrative review discusses the data on efficacy and safety of reperfusion therapy (RT) and neuroprotective therapy in ischemic stroke. The influence of therapy on mortality, residual neurologic deficit and disability is analyzed. It was shown that RT (thrombolysis or mechanical thromboextraction) leads to significant decrease of residual neurologic deficit or disability. The influence of RT on mortality is controversial. There is some evidence that RT can increase early mortality due to hemo…

  20. 104.

    Menon PK, Sharma A, Lafuente JV, Muresanu DF, et al. · International review of neurobiology · 2017 · PMID 29132543

    Influence of iron oxide magnetic nanoparticles (IOMNPs, 10nm in diameter, 0.25 or 0.50mg/mL in 100μL, i.v.) on the blood-brain barrier (BBB) permeability, edema formation, and neuronal or glial changes within 4-24h after administration was examined in normal rats and after a focal spinal cord injury (SCI). Furthermore, effect of cerebrolysin, a balanced composition of several neurotrophic factors, and active peptide fragments was also evaluated on IOMNP-induced changes in central nervous system…

  21. 105.
    TiO

    Wiklund L, Sharma A, Muresanu DF, Zhang Z, et al. · Advances in neurobiology · 2023 · PMID 37480466

    Military personnel during combat or peacekeeping operations are exposed to extreme climates of hot or cold environments for longer durations. Spinal cord injury is quite common in military personnel following central nervous system (CNS) trauma indicating a possibility of altered pathophysiological responses at different ambient temperatures. Our previous studies show that the pathophysiology of brain injury is exacerbated in animals acclimated to cold (5 °C) or hot (30 °C) environments. In thes…

  22. 106.

    Bornstein N, Poon WS · Drugs of today (Barcelona, Spain : 1998) · 2012 · PMID 22514794

    Stroke is one of the most devastating vascular diseases in the world as it is responsible for almost five million deaths per year. Almost 90% of all strokes are ischemic and mainly due to atherosclerosis, cardiac embolism and small-vessel disease. Intracerebral or subarachnoid hemorrhage can lead to hemorrhagic stroke, which usually has the poorest prognosis. Cerebrolysin is a peptide preparation which mimics the action of a neurotrophic factor, protecting stroke-injured neurons and promoting ne…

  23. 107.

    Gavrilova SI, Alvarez A · Medicinal research reviews · 2021 · PMID 32808294

    Alzheimer's disease (AD) is the most common neurocognitive disorder and a global health problem. The prevalence of AD is growing dramatically, especially in low- and middle-income countries, and will reach 131.5 million cases worldwide by 2050. Therefore, developing a disease-modifying therapy capable of delaying or even preventing the onset and progression of AD has become a world priority, and is an unmet need. The pathogenesis of AD, considered as the result of an imbalance between resilience…

  24. 108.

    Sharma HS, Sharma A, Mössler H, Muresanu DF · International review of neurobiology · 2012 · PMID 22748833

    Military personals are often exposed to adverse environmental circumstances, for example, heat stress during peacekeeping or combat operations in summer months or in desert areas leading to disturbed mental functions. The suitable therapeutic strategies to treat heat-induced mental anomalies are still not worked out. Thus, exploration of suitable therapeutic strategies to minimize heat-induced abnormal brain function is needed in suitable animal models. Previous works from our laboratory show th…

  25. 109.

    Masliah E, Díez-Tejedor E · Drugs of today (Barcelona, Spain : 1998) · 2012 · PMID 22514792

    Neurotrophic factors are considered as part of the therapeutic strategy for neurological disorders like dementia, stroke and traumatic brain injury. Cerebrolysin is a neuropeptide preparation which mimics the action of endogenous neurotrophic factors on brain protection and repair. In dementia models, Cerebrolysin decreases β-amyloid deposition and microtubule-associated protein tau phosphorylation by regulating glycogen synthase kinase-3β and cyclin-dependent kinase 5 activity, increases synapt…

  26. 110.

    Grundman M, Corey-Bloom J, Thal LJ · Journal of neural transmission. Supplementum · 1998 · PMID 9700663

    Current treatment approaches in Alzheimer's disease are primarily symptomatic, with the major therapeutic strategy based on acetylcholinesterase inhibition. Alzheimer's disease research should advance over ensuing decade(s) to yield better symptomatic therapies, drugs designed to slow the rate of progression, and disease preventing agents. The next generation of cholinergic agents will include long acting cholinesterase inhibitors with a good safety profile and brain specific muscarinic agonists…

  27. 111.

    Ribó M, Staszewski J, Zeiler SR, Michalak S, et al. · Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2026 · PMID 41349847

    This article provides perspectives on the use of Cerebrolysin as an adjunct treatment to reperfusion therapy in acute ischemic stroke (AIS). In the evolving landscape of AIS reperfusion therapy, we hypothesize that adjunctive cerebroprotective therapy, such as Cerebrolysin, is likely to further improve patient outcomes. Beyond its established neurorecovery benefits, recent data indicate that Cerebrolysin also offers protection to the neurovascular unit and the blood-brain barrier. This paper int…

  28. 112.

    Menon PK, Muresanu DF, Sharma A, Mössler H, et al. · CNS & neurological disorders drug targets · 2012 · PMID 22229324

    Spinal cord injury (SCI) is the world's most disastrous disease for which there is no effective treatment till today. Several studies suggest that nanoparticles could adversely influence the pathology of SCI and thereby alter the efficacy of many neuroprotective agents. Thus, there is an urgent need to find suitable therapeutic agents that could minimize cord pathology following trauma upon nanoparticle intoxication. Our laboratory has been engaged for the last 7 years in finding suitable therap…

  29. 113.

    Sharma HS, Menon PK, Lafuente JV, Aguilar ZP, et al. · Journal of nanoscience and nanotechnology · 2014 · PMID 24730284

    Functionalized Magnetic Iron Oxide Nanoparticles (FMIONPs) are being explored for the development of various biomedical applications, e.g., cancer chemotherapy and/or several other radiological or diagnostic purposes. However, the effects of these NPs per se on the central nervous system (CNS) injury or repair are not well known. This review deals with different aspects of FMIONPs in relation to brain function based on the current literature as well as our own investigation in animal models of C…

  30. 114.

    Muresanu DF, Sharma A, Sahib S, Tian ZR, et al. · Progress in brain research · 2020 · PMID 33223037

    Blast brain injury (bBI) is a combination of several forces of pressure, rotation, penetration of sharp objects and chemical exposure causing laceration, perforation and tissue losses in the brain. The bBI is quite prevalent in military personnel during combat operations. However, no suitable therapeutic strategies are available so far to minimize bBI pathology. Combat stress induces profound cardiovascular and endocrine dysfunction leading to psychosomatic disorders including diabetes mellitus…

  31. 115.

    Sharma A, Muresanu DF, Mössler H, Sharma HS · CNS & neurological disorders drug targets · 2012 · PMID 22229316

    In recent years, the incidence of heat stroke and associated brain pathology are increasing Worldwide. More than half of the world's population are living in areas associated with high environmental heat especially during the summer seasons. Thus, new research is needed using novel drug targets to achieve neuroprotection in heat-induced brain pathology. Previous research from our laboratory showed that the pathophysiology of brain injuries following heat stroke are exacerbated by chronic intoxic…

  32. 116.

    Windisch M, Gschanes A, Hutter-Paier B · Journal of neural transmission. Supplementum · 1998 · PMID 9700665

    In spite that the use of naturally occurring neurotrophic factors like NGF, BDNF, CNTF, GDNF and others for treatment of neurodegenerative disorders seems promising because of their pharmacological properties, until now no large scale clinical trials have been published. One of the reasons is that these molecules are unable to penetrate through the blood brain barrier, making invasive application strategies like intracerebroventricular infusion necessary. Another one is the fact that in first cl…

  33. 117.

    Al-Kuraishy HM, Al-Gareeb AI, Zekry SH, Alruwaili M, et al. · Neuroscience · 2025 · PMID 39832667

    Cerebrolysin (CBL) is a combination of neurotrophic peptides and amino acids derived from pig brains. CBL can cross the blood-brain barrier (BBB) and its biological effect is similar to the effect of endogenous neurotrophic effects. The mechanism of action of CBL is related to the induction of neurogenesis, neuroplasticity, neuroprotection, and neurotrophicity. Therefore, CBL may be effective against the development and progression of neurodegenerative diseases such as Alzheimer disease (AD) and…

  34. 118.

    Sharma A, Muresanu DF, Ozkizilcik A, Tian ZR, et al. · Progress in brain research · 2019 · PMID 30961865

    Sleep deprivation (SD) is very common in military personnel resulting in mental anomalies and interfering with decision-making capabilities. Moreover during combat operation, these sleep-deprived soldiers often receive blunt head trauma casing concussive head injury (CHI). Recent observations clearly suggest that SD alone induces brain pathology and additional CHI further exacerbates brain damage. Thus, the need of the hour is to explore possible effective therapeutic measures to induce neuropro…

  35. 119.

    Matula C, Schoeggl A · Stereotactic and functional neurosurgery · 2000 · PMID 11740183

    Not only the pathology but also the neurosurgical procedure itself can lead to an impairment of cerebral structures. This may cause neurological symptoms like confusion, disorientation or cognitive deficits which have hardly been noticed until now. Neuroprotective substances can help to reduce this. As an example of the effectiveness, based on our own experiences and international trials, two different medical drugs, Nimodipine and Cerebrolysin, are presented. In conclusion one has to realize th…

  36. 120.

    Sharma A, Muresanu DF, Castellani RJ, Nozari A, et al. · Progress in brain research · 2020 · PMID 33223035

    Mild traumatic brain injury (mTBI) is one of the leading predisposing factors in the development of Parkinson's disease (PD). Mild or moderate TBI induces rapid production of tau protein and alpha synuclein (ASNC) in the cerebrospinal fluid (CSF) and in several brain areas. Enhanced tau-phosphorylation and ASNC alters the molecular machinery of the brain leading to PD pathology. Recent evidences show upregulation of constitutive isoform of hemeoxygenase (HO-2) in PD patients that correlates well…

  37. 121.

    Sharma A, Menon PK, Patnaik R, Muresanu DF, et al. · International review of neurobiology · 2017 · PMID 29132541

    More than 5.5 million Americans of all ages are suffering from Alzheimer's disease (AD) till today for which no suitable therapy has been developed so far. Thus, there is an urgent need to explore novel therapeutic measures to contain brain pathology in AD. The hallmark of AD includes amyloid-beta peptide (AβP) deposition and phosphorylation of tau in AD brain. Recent evidences also suggest a marked decrease in neurotrophic factors in AD. Thus, exogenous supplement of neurotrophic factors could…

Research Articles

123
  1. 122.

    Satou T, Itoh T, Tamai Y, Ohde H, et al. · Journal of neural transmission (Vienna, Austria : 1996) · 2000 · PMID 11145001

    We examined the effect of FPF-1070 (Cerebrolysin) on neurite outgrowth in explant cultures of dorsal root ganglia (DRG), sympathetic trunks (ST), and ciliary ganglia (CG) from 10- to 11-day chicken embryos. FPF-1070 significantly promoted neurite outgrowth in DRG and ST neurons at all concentrations examined, in comparison with phosphate buffered saline-treated negative controls; however, this effect on neurite outgrowth was not as significant as that observed for nerve growth factor-treated pos…

  2. 123.

    Sugita Y, Kondo T, Kanazawa A, Itou T, et al. · No to shinkei = Brain and nerve · 1993 · PMID 8334017

    Cerebrolysin (FPF1070) is an extract from pig brain obtained after enzymic digestion, containing free amino acids (85%) and low-molecular weight amino acid sequences (15%). We studied FPF 1070 to determine its ability to protect against delayed neuronal death in the gerbil when administered before and after ischemia. Transient forebrain ischemia was produced by occluding both common carotid arteries. Morphological changes in the CA1 sector of the hippocampus were evaluated 4 days after 5 min. oc…

  3. 124.

    Torshin IY, Gromova OA, Zgoda VG, Tikhonova OV, et al. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2019 · PMID 31994517

    To establish the molecular mechanisms of the mood stabilizing (normothymic) action of the neuroprotector Cerebrolysin. Mass-spectrometric analysis of the peptide composition of cerebrolysin followed by a complex bioinformatics analysis was utilized. Cerebrolysin contains considerable amounts of Leu- and Met-enkephalins, partial analogues of enkephalins, peptide fragments of beta-lipotropin. These peptides stimulate the endorphinergic system thus contributing to normothymic action and an increase…

  4. 125.

    Sharma HS, Muresanu DF, Sharma A · Neurodegenerative disease management · 2016 · PMID 27827552

  5. 126.

    Florek S, Główczyński P, Badura-Brzoza K, Pudlo R · Biomedicines · 2025 · PMID 40722733

  6. 127.

    Strilciuc S, Grad DA, Vlădescu C, Buzoianu AD, et al. · Journal of medicine and life · 2025 · PMID 40405935

    Traumatic brain injuries (TBIs) are a leading cause of death and long-term disability worldwide, with incidence and injury mechanisms varying by age group and region. Impairment of functional status, diagnoses of anxiety and depression are encountered post-TBI. Studies have shown that Cerebrolysin can have positive effects among TBI survivors. We conducted a cost-effectiveness analysis (CEA) among patients with moderate TBI, using data from the CAPTAIN II trial. This exercise was carried out on…

  7. 128.

    Bogolepova AN · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2023 · PMID 36946392

    Cognitive impairment is one of the most important problems of modern health care. Currently, according to WHO, more than 55 million people worldwide are living with dementia. Dementia is one of the leading causes of disability and addiction among older people worldwide. Even more significant is the number of patients with mild cognitive impairment who have an increased risk of progression to dementia compared to people of the same age without cognitive impairment. The number of patients with cog…

  8. 129.

    Sarode LP, Ghatage T, Mardhekar V, Verma B, et al. · Metabolic brain disease · 2023 · PMID 37273080

    Recent preclinical and clinical reports suggest that cerebrolysin shows neuroprotective properties similar to endogenous neurotrophic factors in neurodegenerative disorders including ischemic stroke. However, little is known about its underlying antiexcitotoxic action. Adult male Wistar rats were intraperitoneally treated with cerebrolysin (0.15 or 0.30 mg/kg) or vehicle at 3, 6 and 12 h after ischemic reperfusion and were assessed 24 h after reperfusion in ischemic rats. We added cerebrolysin (…

  9. 130.

    Plosker GL, Gauthier S · CNS drugs · 2010 · PMID 20155999

    Cerebrolysin is a parenterally administered, porcine brain-derived peptide preparation that has pharmacodynamic properties similar to those of endogenous neurotrophic factors. In several randomized, double-blind trials of up to 28 weeks' duration in patients with Alzheimer's disease, Cerebrolysin was superior to placebo in improving global outcome measures and cognitive ability. A large, randomized comparison of Cerebrolysin, donepezil or combination therapy showed beneficial effects on global m…

  10. 131.

    Villarreal-Reyna G, Garza-Morales R, Soto-Domínguez A, Montañez-Guerrero L, et al. · European journal of medical research · 2022 · PMID 36411485

    Hair graying, a prototypical sign of human aging, is a progressive loss of pigmentation from growing hair shafts caused by disease and as a side effect of medications. Cerebrolysin is a neuropeptide preparation that mimics the effect of endogenous neurotrophic factors. Cerebrolysin has been widely used in neurologic conditions, such as cerebral stroke, Alzheimer's disease, and dementia, among others. Cerebrolysin treatment has achieved to regain or maintain the cognitive ability of affected pati…

  11. 132.

    Antón Álvarez X, Fuentes P · Drugs of today (Barcelona, Spain : 1998) · 2011 · PMID 22013558

    Cerebrolysin is a neuropeptide preparation mimicking the action of endogenous neurotrophic factors. Positive effects of Cerebrolysin on β-amyloid- and tau-related pathologies, neuroinflammation, neurotrophic factors, oxidative stress, excitotoxicity, neurotransmission, brain metabolism, neuroplasticity, neuronal apoptosis and degeneration, neurogenesis and cognition were demonstrated in experimental conditions. These pleiotropic effects of Cerebrolysin on Alzheimer's disease-related pathogenic e…

  12. 133.
  13. 134.

    DeBoer SR, Hubbard R, Mersha M, Pinilla Monsalve G, et al. · Neurorehabilitation and neural repair · 2021 · PMID 33955296

    Motor recovery after stroke in humans and in rodent models is time sensitive. Recovery in patients is a result of biological spontaneous recovery via endogenous repair mechanisms and is likely improved by enhancing the synaptic plasticity required for endogenous repair. Cerebrolysin is a polypeptide preparation known to enhance neuroplasticity and may improve recovery in patients. In mice, we tested the hypothesis that Cerebrolysin can act poststroke to enhance both spontaneous and training-asso…

  14. 135.

    Vosko MR, Sanak D, Do Y, Vatanagul JS, et al. · International journal of stroke : official journal of the International Stroke Society · 2025 · PMID 40851188

    The main objective of the Cerebrolysin REGistry Study in Stroke 2 (C-REGS2) was to systematically record the routine clinical use of Cerebrolysin in patients with moderate ischemic stroke (IS) following the principles of a prospective controlled effectiveness study (CES) to compare its effectiveness in terms of functional recovery to patients treated with standard therapy alone. C-REGS2 used an open-label, prospective controlled comparative effectiveness design aligning with the Target Trial Emu…

  15. 136.

    Morega S, Gresita A, Mitran SI, Musat MI, et al. · Life (Basel, Switzerland) · 2022 · PMID 36362945

    The treatment of acute life-threatening events in patients suffering from chronic pathologies is problematic, as physicians need to consider multisystemic drug effects. Regarding Cerebrolysin, a Sonic Hedgehog signaling pathway amplifier and one of the few approved neurotrophic treatments for stroke patients, concerns of excessive Hedgehog pathway activation that could accelerate NAFLD progression to cirrhosis seem valid. We investigated stroke patients treated with Cerebrolysin that presented e…

  16. 137.

    Kastberger B, Winter S, Brandstätter H, Biller J, et al. · Advanced biology · 2024 · PMID 38062874

    Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a rare familial neurological disorder caused by mutations in the NOTCH3 gene and characterized by migraine attacks, depressive episodes, lacunar strokes, dementia, and premature death. Since there is no therapy for CADASIL the authors investigate whether the multi-modal neuropeptide drug Cerebrolysin may improve outcome in a murine CADASIL model. Twelve-month-old NOTCH3

  17. 138.

    Tharwat EK, Abdelaty AO, Abdelrahman AI, Elsaeed H, et al. · Metabolic brain disease · 2023 · PMID 36847968

    Parkinson's disease (PD) is the second most prevalent neurodegenerative disease worldwide and represents a challenge for clinicians. The present study aims to investigate the effects of cerebrolysin and/or lithium on the behavioral, neurochemical and histopathological alterations induced by reserpine as a model of PD. The rats were divided into control and reserpine-induced PD model groups. The model animals were further divided into four subgroups: rat PD model, rat PD model treated with cerebr…

  18. 139.

    Abdelaty AO, Tharwat EK, Abdelrahman AI, Elgohary A, et al. · Journal of psychiatric research · 2024 · PMID 38394763

    Depression is the most prevalent psychiatric disorder worldwide. Although numerous antidepressant treatments are available, there is a serious clinical concern due to their severe side effects and the fact that some depressed patients are resistant to them. Lithium is the drug of choice for bipolar depression and has been used as adjunct therapy with other groups of antidepressants. The present study aims to investigate the effect of lithium augmentation with cerebrolysin on the neurochemical, b…

  19. 140.

    Tran L, Alvarez XA, Le HA, Nguyen DA, et al. · CNS & neurological disorders drug targets · 2022 · PMID 34414874

    To investigate the efficacy and safety of Cerebrolysin and Cerebrolysin plus nootropics in the routine treatment of patients with acute ischemic stroke (AIS). Acute ischemic stroke (AIS) is a leading cause of disability with unmet treatment needs lacking effective drug therapy. Multimodal drugs modulating stroke pathophysiology as Cerebrolysin constitute a good therapeutic option. In this study, we assessed the effects of Cerebrolysin and Cerebrolysin plus nootropics, in comparison with other no…

  20. 141.

    Kojder K, Jarosz K, Andrzejewska A, Solek-Pastuszka J, et al. · Biomedicines · 2024 · PMID 39595058

  21. 142.

    Kurkin DV, Bakulin DA, Morkovin EI, Kalatanova AV, et al. · PloS one · 2021 · PMID 34260655

    This study was the first to compare the neuroprotective activity of Cerebrolysin®, Actovegin® and Cortexin® in rodent models of acute and chronic brain ischemia. The neuroprotective action was evaluated in animals with acute (middle cerebral artery occlusion) or chronic (common carotid artery stenosis) brain ischemia models in male rats. Cortexin® (1 or 3 mg/kg/day), Cerebrolysin® (538 or 1614 mg/kg/day) and Actovegin® (200 mg/kg/day) were administered for 10 days. To assess the neurological and…

  22. 143.

    Mafikandi V, Hosseini L, Seyedaghamiri F, Mansourian H, et al. · Molecular biology reports · 2025 · PMID 40668305

    Cerebrolysin (CBL), a peptide derived from pig brain, is recognized for its neuroprotective and anti-inflammatory properties. This research aimed to investigate the effects of CBL on anxiety- and depression-like behaviors, spatial memory, the tryptophan/kynurenine (TRP/KYN) pathway, and inflammation in the prefrontal cortex (PFC) of a mouse model for schizophrenia. Thirty-six male BALB/c mice were allocated into three experimental groups: control, ketamine (Ket) (20 mg/kg per day, i.p.), and Ket…

  23. 144.

    Gromova OA, Pronin AV, Torshin IY, Kalacheva AG, et al. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2016 · PMID 28091504

    To investigate the effect of cerebrolysin on the growth and metastasis of malignant tumors in mice (a model of lung carcinoma Lewis). The study was performed on 60 male mice, hybrids F1 (the age of 2-2.5 months, body weight 19-22g.). Transplantable epidermoid Lewis lung carcinoma (LLC) was used as a standard experimental model to evaluate the properties of the potential antitumor agents. Experimental animals were administered a single intraperitoneal injection of cerebrolysin in doses of 524 mg/…

  24. 145.

    Strilciuc S, Radu C, Grad DA, Stan AD, et al. · Healthcare (Basel, Switzerland) · 2023 · PMID 37239783

    The cost-effectiveness of Cerebrolysin as an add-on therapy for moderate-severe acute ischemic stroke is a topic that remains understudied. This study aims to address this gap by performing a comprehensive cost-utility analysis using both deterministic and probabilistic methods from a payer perspective and within the Romanian inpatient care setting. Quality-adjusted life years (QALYs) were calculated using partial individual patient data from the 2016 Cerebrolysin and Recovery After Stroke (CARS…

  25. 146.

    Markus HS · International journal of stroke : official journal of the International Stroke Society · 2025 · PMID 41126602

  26. 147.

    Zhang Y, Chopp M, Meng Y, Zhang ZG, et al. · Journal of neurosurgery · 2015 · PMID 25614944

    Long-term memory deficits occur after mild traumatic brain injuries (mTBIs), and effective treatment modalities are currently unavailable. Cerebrolysin, a peptide preparation mimicking the action of neurotrophic factors, has beneficial effects on neurodegenerative diseases and brain injuries. The present study investigated the long-term effects of Cerebrolysin treatment on cognitive function in rats after mTBI. Rats subjected to closed-head mTBI were treated with saline (n = 11) or Cerebrolysin…

  27. 148.

    Kang DH, Choi BY, Lee SH, Kho AR, et al. · Frontiers in neuroscience · 2020 · PMID 33177978

    Epilepsy is one of the most common and severe brain diseases. The exact cause of epilepsy is unclear. Epilepsy often occurs following brain damage, such as traumatic brain injury (TBI) and ischemia. Cerebrolysin is a porcine brain peptide that is a unique neurotropic and neuroprotective agent. Cerebrolysin has been reported to increase neuroprotective effects after TBI, ischemia, and other CNS diseases. However, the effects of cerebrolysin on seizures are not known. Therefore, this study aimed t…

  28. 149.

    Sharma HS, Feng L, Chen L, Huang H, et al. · Neurochemical research · 2023 · PMID 36719560

    Neuropathic pain is associated with abnormal sensations and/or pain induced by non-painful stimuli, i.e., allodynia causing burning or cold sensation, pinching of pins and needles like feeling, numbness, aching or itching. However, no suitable therapy exists to treat these pain syndromes. Our laboratory explored novel potential therapeutic strategies using a suitable composition of neurotrophic factors and active peptide fragments-Cerebrolysin (Ever Neuro Pharma, Austria) in alleviating neuropat…

  29. 150.

    Yazar U, Guvercin AR, Rouhikia M, Aktoklu M, et al. · Journal of receptor and signal transduction research · 2023 · PMID 38079610

    Cerebrolysin, an endogenous peptide with neuroprotective and neurotrophic properties, indicated to be beneficial on diabetic neuropathy by preliminary clinical and experimental studies but without evidence on central or peripheral action. Dorsal root ganglion (DRG) neurons, based on involvement of pain sensation in both health and disease as first relay centers for transmission and processing of peripheral nociceptive sensory signals, was used to investigate possible effects of Cerebrolysin on h…

  30. 151.

    Abolhasanpour N, Eidi A, Hajebrahimi S, Reyhani-Rad S, et al. · International journal of urology : official journal of the Japanese Urological Association · 2019 · PMID 31317583

    To study the effect of cerebrolysin on bladder function after spinal cord injury using functional measurements in rats. A total of 60 female rats were enrolled in this study. After induction of complete transection at T9-T10 spinal vertebrae, cerebrolysin was injected intraperitoneally, and daily in three dosages until 7 days (1 week) and continued until 28 days (4 weeks) in three groups to show the impact of that on the bladder function. Urodynamic parameters were measured in the different grou…

  31. 152.

    Tonge C, Bektasoglu PK, Gulmez A, Turkoglu ME, et al. · Turkish neurosurgery · 2023 · PMID 37309634

    To investigate the effects of cerebrolysin on inflammation, oxidative stress, apoptosis, and neurologic recovery in the setting of an experimental rabbit model of spinal cord ischemia/reperfusion injury (SCIRI). Rabbits were randomly divided into five groups: control, ischemia, vehicle, methylprednisolone (30 mg/kg), and cerebrolysin (5 ml/kg) group. The rabbits in the control group underwent only laparotomy; the other groups underwent spinal cord ischemia and reperfusion injury for 20 minutes.…

  32. 153.

    Avci S, Gunaydin S, Ari NS, Karaca Sulukoglu E, et al. · Journal of molecular neuroscience : MN · 2022 · PMID 36333611

    Glutamate, one of the most important excitatory neurotransmitters, acts as a signal transducer in peripheral tissues and endocrine cells. Excessive glutamate secretion has been shown to cause excitotoxicity and neurodegenerative disease. Cerebrolysin is a mixture of enzymatically treated peptides derived from pig brain including neurotrophic factors, like brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrop…

  33. 154.

    Zhang Y, Chopp M, Zhang ZG, Zhang Y, et al. · Neurorehabilitation and neural repair · 2019 · PMID 30499355

    Cerebrolysin is a neuropeptide preparation with neuroprotective and neurotrophic properties. Our previous study demonstrates that cerebrolysin significantly improves functional recovery in rats after mild traumatic brain injury (mTBI). To determine histological outcomes associated with therapeutic effects of cerebrolysin on functional recovery after TBI. In this prospective, randomized, blinded, and placebo-controlled study, adult Wistar rats with mild TBI induced by a closed head impact were ra…

  34. 155.

    Farajdokht F, Oghbaei F, Sadigh-Eteghad S, Majdi A, et al. · Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2022 · PMID 35500360

    This study examined the beneficial effects of cerebrolysin (CBL) and enriched environment (EE), alone or in combination, on the neurobehavioral and molecular changes in the post-ischemic depression (PID) model in mice. PID was induced in male Balb/c mice (25-30 g) by combining the transient bilateral common carotid artery occlusion (bCCAO), twice for 5 min at the interval of 10 min, with spatial restraint stress (2 h/day) for 2 weeks, started 48 h following the establishment of bCCAO model. Anim…

  35. 156.

    Verisezan Rosu O, Jemna N, Hapca E, Benedek I, et al. · Frontiers in neuroscience · 2023 · PMID 37360156

    Traumatic brain injury (TBI) is a major public health problem affecting millions worldwide. Despite significant advances in medical care, there are limited effective interventions for improving cognitive and functional outcomes in TBI patients. This randomized controlled trial investigated the safety and efficacy of combining repetitive transcranial magnetic stimulation (rTMS) and Cerebrolysin in improving cognitive and functional outcomes in TBI patients. Ninety-three patients with TBI were ran…

  36. 157.

    Zhang L, Chopp M, Meier DH, Winter S, et al. · Stroke · 2013 · PMID 23696546

    Cerebrolysin, a mixture of neurotrophic peptides, enhances neurogenesis and improves neurological outcome in experimental neurodegenerative diseases and stroke. The Sonic hedgehog (Shh) signaling pathway stimulates neurogenesis after stroke. The present study tests whether the Shh pathway mediates cerebrolysin-induced neurogenesis and improves neurological outcome after stroke. Rats subjected to embolic stroke were treated with cerebrolysin with or without cyclopamine. Using neural progenitor ce…

  37. 158.

    Lucena LLN, Briones MVA · Clinical neurology and neurosurgery · 2022 · PMID 35344761

    Severe traumatic brain injury (TBI) patients with nonoperative lesions are known to have a poorer prognosis. Recent and ongoing clinical studies have been exploring the utility of Cerebrolysin in improving patient outcomes among TBI patients; however, few studies are available on the effect of Cerebrolysin among nonoperative severe TBI patients. To determine the effects of Cerebrolysin as add-on therapy to the standard medical decompression protocol for nonoperative severe TBI patients. The stud…

  38. 159.

    Seidl LF, Aigner L · Journal of medicine and life · 2024 · PMID 38737662

    Neurological disorders, ranging from acute forms such as stroke and traumatic brain injury to neurodegenerative diseases like dementia, are the leading cause of disability-adjusted life years (DALYs) worldwide. A promising approach to address these conditions and promote nervous system regeneration is the use of the neuropeptide preparation Cerebrolysin, which has been shown to be effective in both clinical and preclinical studies. Despite claims of similar clinical efficacy and safety by severa…

  39. 160.

    Alzoubi KH, Al-Ibbini AM, Nuseir KQ · Psychiatry research · 2018 · PMID 30316170

    Post-traumatic stress disorder (PTSD) may occur after exposure to stressful, fearful or troubling events. Until now, there is no curable medication for this disorder. Cerebrolysin is a neuropeptide, which has an important role in the treatment of vascular dementia. In this study, the probable protective effect of cerebrolysin on PTSD-induced memory impairment was investigated. To induce PTSD, the single prolonged stress (SPS) model was used. Rats were allocated into four groups: control (vehicle…

  40. 161.

    von Wild T, Brunelli GA, von Wild KRH, Löhnhardt M, et al. · Journal of medicine and life · 2019 · PMID 32025252

    The restoration of voluntary muscle activity in posttraumatic paraplegia in both animal experiments and other clinical applications requires reproducibility of a technically-demanding microsurgical procedure, limited by physicians' understanding of Brunelli's spinal cord grafting paradigm. The insufficient clinical investigation of the long-term benefits of the CNS-PNS graft application warrants additional inquiry. The objective of this study is to explore the potential benefits of the first rep…

  41. 162.

    Hartwig K, Fackler V, Jaksch-Bogensperger H, Winter S, et al. · International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience · 2014 · PMID 25093704

    Cerebrolysin (EVER Neuro Pharma GmbH, Austria) is a peptidergic drug indicated for clinical use in stroke, traumatic brain injury and dementia. The therapeutic effect of Cerebrolysin is thought to ensure from its neurotrophic activity, which shares some properties with naturally occurring neurotrophic factors. However, the exact mechanism of action of Cerebrolysin is yet to be fully deciphered. This study aimed to investigate the neuroprotective effect of Cerebrolysin in a widely used in vitro m…

  42. 163.

    Sharma A, Feng L, Muresanu DF, Tian ZR, et al. · International review of neurobiology · 2023 · PMID 37783554

    Sleep deprivation is quite frequent in military during combat, intelligence gathering or peacekeeping operations. Even one night of sleep deprivation leads to accumulation of amyloid beta peptide burden that would lead to precipitation of Alzheimer's disease over the years. Thus, efforts are needed to slow down or neutralize accumulation of amyloid beta peptide (AβP) and associated Alzheimer's disease brain pathology including phosphorylated tau (p-tau) within the brain fluid environment. Sleep…

  43. 164.

    Yang B, Li Y, Guo W, Zhang Q, et al. · Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2023 · PMID 37220681

    Cerebrolysin (CBL) is a peptide-rich preparation made by hydrolysis and purified extraction of porcine brain. CBL contains various neuroprotective peptides, such as neurotrophic factor, nerve growth factor and ciliary neurotrophic factor, which can be used to treat neurodegenerative diseases. However, the active peptides in CBL had not been studied in depth. In this study, the following was carried out in order to investigate the active peptides in CBL. First, CBL samples were treated using orga…

  44. 165.

    Olivia VR, Chira D, Chelaru VF, Diana CD, et al. · Journal of medicine and life · 2024 · PMID 39044922

    This secondary analysis of the CAPTAIN-RTMS trial data focused on the significance of quantitative electroencephalography (qEEG) indices as indicators of recovery in patients with traumatic brain injury (TBI). By focusing on the delta alpha ratio (DAR), delta theta/alpha beta ratio (DTABR), and theta beta ratio (TBR), this study explored the shifts in brainwave activity as a response to an integrative treatment regimen of repetitive transcranial magnetic stimulation (rTMS) combined with the neur…

  45. 166.

    Dubový P, Raška O, Klusáková I, Stejskal L, et al. · BMC neuroscience · 2011 · PMID 21696588

    It is difficult to repair nerve if proximal stump is unavailable or autogenous nerve grafts are insufficient for reconstructing extensive nerve damage. Therefore, alternative methods have been developed, including lateral anastomosis based on axons' ability to send out collateral sprouts into denervated nerve. The different capacity of a sensory or motor axon to send a sprout is controversial and may be controlled by cytokines and/or neurotrophic factors like ciliary neurotrophic factor (CNTF).…

  46. 167.

    Abdel-Salam OM, Omara EA, Mohammed NA, Youness ER, et al. · Drug discoveries & therapeutics · 2013 · PMID 24423658

    This study aimed to investigate the effect of cerebrolysin on oxidative stress in the brain and liver during systemic inflammation. Rats were intraperitoneally challenged with a single subseptic dose of lipopolysaccharide (LPS; 300 μg/kg) without or with cerebrolysin at doses of 21.5, 43 or 86 mg/kg. After 4 h, rats were euthanized and the brain and liver tissues were subjected to biochemical and histopathological analyses. Cerebrolysin revealed inhibitory effects on the elevation of lipid perox…

  47. 168.

    Jarosz K, Kojder K, Skonieczna-Żydecka K, Andrzejewska A, et al. · Journal of clinical medicine · 2024 · PMID 38256487

    Traumatic brain injury (TBI) is one of the most common causes of death and an important burden to the worldwide healthcare system and society. There is a lack of guidelines for types of monitoring or neuroprotective therapy. The aim of this pilot study was to assess its feasibility and, furthermore, to evaluate the impact of Cerebrolysin on the following clinical outcomes: length of stay, Glasgow Outcome Scale (GOS) and mortality. A cohort of 56 patients was included in this non-randomised, real…

  48. 169.

    Soto C, Salinas P, Muñoz D, Olivares S, et al. · Journal of medicine and life · 2023 · PMID 37900065

    In this retrospective study, we aimed to evaluate the effects of the neurotrophic compound Cerebrolysin on executive, cognitive, and functional performance in patients with traumatic brain injury (TBI) with a highly severe disability level. A total of 44 patients were included in the study, with 33 patients in the control group and 11 patients in the interventional group who received intravenous infusions of 30 mL Cerebrolysin. Both groups received standard rehabilitation therapy following the r…

  49. 170.

    Catalin B, Rogoveanu OC, Pirici I, Balseanu TA, et al. · CNS & neurological disorders drug targets · 2018 · PMID 29692268

    Edema represents one of the earliest negative markers of survival and consecutive neurological deficit following stroke. The mixture of cellular and vasogenic edema makes treating this condition complicated, and to date, there is no pathogenically oriented drug treatment for edema, which leaves parenteral administration of a hypertonic solution as the only non-surgical alternative. New insights into water metabolism in the brain have opened the way for molecular targeted treatment, with aquapori…

  50. 171.

    Keilhoff G, Lucas B, Pinkernelle J, Steiner M, et al. · Experimental cell research · 2014 · PMID 24997385

    Although the peripheral nervous system is capable of regeneration, this capability is limited. As a potential means of augmenting nerve regeneration, the effects of cerebrolysin (CL)--a proteolytic peptide fraction--were tested in vitro on the motor-neuron-like NSC-34 cell line and organotypic spinal cord cultures. Therefore, NSC-34 cells were subjected to mechanical stress by changing media and metabolic stress by oxygen glucose deprivation. Afterwards, cell survival/proliferation using MTT and…

  51. 172.

    Martínez-Torres NI, Cárdenas-Bedoya J, Torres-Mendoza BM · Neurochemical research · 2024 · PMID 39580783

    Lesions in the motor cortex induced by contusions or pathological insults can exert the degeneration of afferent neurons lying distal to these lesions. Axon degeneration and demyelination are hallmarks of several diseases sharing pathophysiological and clinical characteristics. These conditions are very disabling due to the disruption of motor abilities, with lesions that affect this area proving to be a therapeutic challenge, which has driven increasing efforts to search for treatments. Cerebro…

  52. 173.

    Martinez RM · Journal of medicine and life · 2017 · PMID 29075344

    This study assessed the efficacy of Cerebrolysin on post-stroke spasticity, motor recovery, and global functions in an outpatient rehabilitation setting. In this retrospective comparison study, Cerebrolysin was administered at a daily dosage of 10 ml for over 30 days as an intramuscular injection. Control patients did not receive Cerebrolysin. All the patients participated in a standardized physical and occupational rehabilitation therapy for one month at least two times per week. Efficacy was a…

  53. 174.

    Alzoubi KH, Al-Jamal FF, Mahasneh AF · Physiology & behavior · 2020 · PMID 31987894

    Sleep plays a critical role in body health maintenance and well-being throughout a lifetime. Sleeplessness is the most prevalent feature in the modernist societies, which impairs memory. Studies have shown a strong correlation between sleep deprivation and memory impairment in humans and animals, which is related to oxidative stress induced damage within the brain. Cerebrolysin (CBL) is a neuropeptide that is used to treat vascular dementia. In this study, the effect of CBL on sleep-deprivation…

  54. 175.

    Mallory M, Honer W, Hsu L, Johnson R, et al. · Acta neuropathologica · 1999 · PMID 10334480

    Recent studies have shown that Cerebrolysin can enhance synaptic function and ameliorate synaptodendritic alterations in animal models of neurodegeneration, suggesting a synaptotrophic effect. We hypothesize that Cerebrolysin might exert this effect, in part, by regulating the expression of amyloid precursor protein (APP). We studied the patterns of expression of synaptic proteins during differentiation of human teratocarcinoma cell line NTera 2 (NT2) in the presence or absence of Cerebrolysin.…

  55. 176.

    Alvarez XA, Alvarez I, Martinez A, Romero I, et al. · The international journal of neuropsychopharmacology · 2020 · PMID 32640027

    Serum vascular endothelial growth factor (VEGF) increases with Alzheimer's disease (AD) severity and may prevent cognitive decline. However, information on the influence of AD drug therapy on circulating VEGF is limited. This study assessed changes in serum VEGF levels and its association with clinical and functional responses in mild to moderate AD patients who were treated with Cerebrolysin, donepezil, or the combined therapy in a randomized, controlled trial. Treatment with Cerebrolysin plus…

  56. 177.

    Park YK, Yi HJ, Choi KS, Lee YJ, et al. · Advances in therapy · 2018 · PMID 30414051

    Cerebrolysin is a neuroprotective drug used in the treatment of acute ischemic stroke. To our knowledge, this drug has never been evaluated in patients with aneurysmal subarachnoid hemorrhage (SAH). The aim of this study was to evaluate the effect of Cerebrolysin in patients with aneurysmal SAH. Aneurysmal SAH patients who had their aneurysm obliterated at our institution from 2007 to 2016 were retrospectively studied. Patients received Cerebrolysin treatment or standard care only (control group…

  57. 178.

    Muresanu DF, Sharma A, Tian ZR, Lafuente JV, et al. · Advances in neurobiology · 2023 · PMID 37480463

    Blast brain injury (bBI) following explosive detonations in warfare is one of the prominent causes of multidimensional insults to the central nervous and other vital organs injury. Several military personnel suffered from bBI during the Middle East conflict at hot environment. The bBI largely occurs due to pressure waves, generation of heat together with release of shrapnel and gun powders explosion with penetrating and/or impact head trauma causing multiple brain damage. As a result, bBI-induce…

  58. 179.

    Safarova TP, Gavrilova SI · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2020 · PMID 33205930

    Comparative evaluation of the effectiveness and safety of antidepressant monotherapy and combined antidepressant therapy with the inclusion of neuroprotectors in the treatment of depression in old and very old patients in a psychiatric hospital. The study included 2 groups of patients from the cohort of patients hospitalized in the gerontopsychiatric unit with mild and moderate depression (according to the ICD-10 classification) aged 60 years and older. The groups are comparable in their main de…

  59. 180.

    Teng H, Li C, Zhang Y, Lu M, et al. · Neuroreport · 2021 · PMID 33661804

    Cerebrolysin has been shown to promote neurovascular protection and repair in preclinical models of stroke and neural injury and is demonstrating promise for stroke and neural injury therapeutic application in the clinic. The effect of Cerebrolysin on the human cerebral endothelial cell function has not been investigated. Using an in-vitro cerebral endothelial cell permeability assay and western blot analyses of tight junction and proinflammatory and procoagulant proteins, the present study show…

  60. 181.

    Martínez-Torres NI, Cárdenas-Bedoya J, Torres-Mendoza BM · Neuroscience · 2024 · PMID 38734304

    Stroke is one of the leading causes of disability worldwide, where the Hippocampus (HPC) is affected. HPC organizes memory, which is a cognitive domain compromised after a stroke, where cerebrolysin (CBL) and Nicotinamide (NAM) have been recognized as potentially therapeutic. In this study, we aimed to evaluate the efficacy of a combined administration of CBL and NAM in a rat stroke model. Male Sprague-Dawley rats (n = 36) were divided into four groups: saline (pMCAO - Saline), CBL (pMCAO + CBL)…

  61. 182.

    Kalinin MN, Khasanova DR · Frontiers in pharmacology · 2023 · PMID 38249342

  62. 183.

    Firstenfeld AJ · Journal of medicine and life · 2024 · PMID 38813353

  63. 184.
  64. 185.

    Martínez-Torres NI, Cárdenas-Bedoya J, Vázquez-Torres BM, Torres-Mendoza BM · Brain research · 2024 · PMID 38048977

    Stroke is a pathology related to the vascular system in the brain and it is one of the main causes of disability, representing a burden on public health. This lesion provokes a disorganization of sensory-motor and cognitive systems, the latter associated with hippocampal activity, a structure in which α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and NMDA N-methyl-D-aspartate (NMDA) receptors are important for the integration of information. Several molecules have been studied for…

  65. 186.

    Aguilar-Hernández L, Gómez-Villalobos MJ, Flores G · Synapse (New York, N.Y.) · 2020 · PMID 32232874

    Hyperglycemia of diabetes mellitus causes damage at the vascular level, which at the renal level represents diabetic nephropathy. In this pathology, there is arterial hypertension. In addition, several reports suggest that hyperglycemia and arterial hypertension affect interneuronal communication at the level of dendritic morphology. We studied these changes in an animal model with streptozotocin-induced diabetes mellitus in the spontaneous hypertensive (SH) rat. Recent reports from our laborato…

  66. 187.

    Flores-Páez LA, Pacheco-Rosado J, Alva-Sánchez C, Zamudio SR · Behavioural pharmacology · 2020 · PMID 31850962

    Aging reduces the efficiency of the organs and systems, including the cognitive functions. Brain aging is related to a decrease in the vascularity, neurogenesis, and synaptic plasticity. Cerebrolysin, a peptide and amino acid preparation, has been shown to improve the cognitive performance in animal models of Alzheimer's disease. Similarly, the leucine-rich repeat transmembrane 4 protein exhibits a strong synaptogenic activity in the hippocampal synapses. The aim of this study was to evaluate th…

  67. 188.

    Selezneva ND, Gavrilova SI · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2023 · PMID 37655416

    To evaluate the long-term effects of annual course therapy with Cerebrolysin on cognitive functioning and the risk of transition to dementia in relatives of patients with Alzheimer's disease (AD) with amnestic-type mild cognitive decline syndrome (aMCI) in comparison with the same group untreated relatives. The cohort included 88 first-degree relatives of BA patients with aMCI syndrome aged 50 to 82 years (mean age 65.0±9.9 years) of which 46 people received course therapy with Cerebrolysin and…

  68. 189.

    Zhang Y, Chopp M, Meng Y, Zhang ZG, et al. · Journal of neurosurgery · 2013 · PMID 23581594

    Cerebrolysin is a unique peptide preparation that mimics the action of neurotrophic factors. This study was designed to investigate the effects of acute treatment of experimental closed head injury (CHI) in rats with Cerebrolysin on neurological function. Adult male Wistar rats (n = 60) were subjected to impact acceleration-induced CHI. Closed head injured rats received intraperitoneal injection of saline (n = 30) or Cerebrolysin (2.5 ml/kg, n = 30) starting 1 hour postinjury and administered on…

  69. 190.

    Espinoza I, Cabrera F, Morales-Medina JC, Gómez-Villalobos MJ, et al. · Behavioural brain research · 2024 · PMID 38897418

    Diabetes mellitus (DM) is a metabolic disorder impacting cerebral function. The administration of Streptozotocin (STZ) is a well-known animal model of insulinopenic type 1 DM in rats. STZ-induced DM results in a myriad of alteration in the periphery and central nervous system (CNS). Cerebrolysin (CBL) is a neuropeptide preparation that promotes synaptic and neuronal plasticity in various animal models. In all cases, CBL was administered when the model was established. This research aims to inves…

  70. 191.

    Sharma HS, Zimmermann-Meinzingen S, Sharma A, Johanson CE · Acta neurochirurgica. Supplement · 2010 · PMID 19812972

    The possibility that Cerebrolysin, a mixture of several neurotrophic factors, has some neuroprotective effects on whole body hyperthermia (WBH) induced breakdown of the blood-brain barrier (BBB), blood-CSF barrier (BCSFB), brain edema formation and neuropathology were examined in a rat model. Rats subjected to a 4 h heat stress at 38 degrees C in a biological oxygen demand (BOD) incubator exhibited profound increases in BBB and BCSFB permeability to Evans blue and radioiodine tracers compared to…

  71. 192.

    Pourmemar E, Majdi A, Haramshahi M, Talebi M, et al. · Experimental gerontology · 2017 · PMID 27894939

    Neurotrophic factors are currently being considered as pro-cognitive therapeutic approaches for management of cognitive deficits. This study aims to evaluate the effects of intranasal (i.n.) or intraperitoneal (i.p.) administration of Cerebrolysin (CBL) (as a mixture of neurotrophic factors) on the d-galactose-induced oxidative stress, apoptosis and memory as well as learning impairment in mice. For this purpose, CBL (1, 2.5, 5 ml/kg/i.p.) or (1 ml/kg/i.n.), were administrated daily in d-galacto…

  72. 193.

    Dong HY, Jiang XM, Niu CB, Du L, et al. · Neural regeneration research · 2016 · PMID 26981106

    To examine the effects of Cerebrolysin on the treatment of diabetic peripheral neuropathy, we first established a mouse model of type 2 diabetes mellitus by administering a high-glucose, high-fat diet and a single intraperitoneal injection of streptozotocin. Mice defined as diabetic in this model were then treated with 1.80, 5.39 or 8.98 mL/kg of Cerebrolysin via intraperitoneal injections for 10 consecutive days. Our results demonstrated that the number, diameter and area of myelinated nerve fi…

  73. 194.

    Calderón Guzmán D, Brizuela NO, Ortíz Herrera M, Hernández García E, et al. · Acta pharmaceutica (Zagreb, Croatia) · 2016 · PMID 27383892

    The study tested the hypothesis that cerebrolysin protects the brain from free radicals in rats treated with 3-nitropropionic acid (3-NPA). To address this hypothesis, the levels of dopamine (DA) and some oxidative stress biomarkers were measured after administration of 3-NPA. Young male Fischer rats were treated for three days with cerebrolysin, 3-NPA or both substances. Their brains were extracted, and DA, lipid peroxidation (LP), glutathione (GSH), calcium, and H2O2 were measured using valida…

  74. 195.
  75. 196.
  76. 197.
  77. 198.

    Baran H, Kronsteiner C. · 2026 · PMID 42072724

    Kynurenic acid (KYNA), a metabolite of the L-kynurenine pathway of L-tryptophan degradation, is an endogenous blocker of glutamate ionotropic excitatory amino acid (EAA) receptors and nicotinic acetylcholine receptors (nAChRs). KYNA plays a significant role in various neuropsychiatric disorders and the aging process. Some researchers have suggested that KYNA may contribute to memory impairment. In this study, we examined the impact of L-kynurenine (a KYNA substrate) and the anti-dementia drugs D…

  78. 199.
  79. 200.

    Staszewski J, Dębiec A, Gniadek-Olejniczak K, Stępień A, Piusinska-Macoch R, Strilciuc S, Balo D, Harston G, Brzozowski K, Zięcina P, Narloch J, Wierzbicki M, Piasecki P. · 2026 · PMID 41739286

    Background Long-term outcomes after endovascular thrombectomy (EVT) and the role of adjunctive neuroprotection to achieve post-stroke independence remain incompletely characterized. In this hypothesis-generating target-trial emulation, we assessed 12-month functional outcomes in a prespecified extension of a propensity score-matched cohort of rigorously selected EVT patients treated with adjunctive Cerebrolysin, a multimodal neuroprotective agent. Methods Consecutive EVT patients were prospectiv…

  80. 201.

    Alrabadi B, Alghzawi Y, Bandak N. · 2026 · PMID 41775380

  81. 202.
  82. 203.

    Kalinin MN, Khasanova DR. · 2025 · PMID 41640685

    <h4>Background</h4>The optimal timing of anticoagulation resumption after acute ischemic stroke remains uncertain, particularly in patients at elevated risk of hemorrhagic transformation (HT). Although Cerebrolysin reduces HT incidence, its influence on dynamic HT risk and the safe anticoagulation window remains unclear.<h4>Methods</h4>This <i>post hoc</i> secondary survival analysis of the CEREHETIS trial (ISRCTN87656744) included 238 patients with intravenous thrombolysis (IVT)-treated middle…

  83. 204.
  84. 205.

    Shmonin AA, Kashaev IK, Luchinin EA, Bakulin GS. · 2026 · PMID 41782528

    <h4>Objective</h4>To evaluate the effect of Cerebrolysin on improving the process of skill formation in patients with acute cerebrovascular accident during medical rehabilitation, based on a systematic review of the literature using elements of meta-analysis.<h4>Material and methods</h4>A search of publications was conducted using the keywords «Cerebrolysin; Rehabilitation; Arm; Speech; Occupational therapy; Physical therapy; Ergotherapy» in the PubMed, Google Scholar and Elibrary databases. Ori…

  85. 206.

    Khatkova SE, Pavlyuchenkova OS, Golovanova AV, Larin AS. · 2026 · PMID 41661016

    This report presents a clinical case of a 39-year-old patient with severe right-sided hemiparesis and complex motor aphasia in the late recovery phase of ischemic stroke (IS). Alongside comprehensive physical rehabilitation and speech therapy sessions, the patient received several courses of intravenous Cerebrolysin at a dose of 20 ml (10 infusions). Efficacy was assessed using the Modified Rankin Scale (mRS), Barthel Index, Rivermead Mobility Index, Berg Balance Scale, Hauser Ambulation Index,…

  86. 207.

    Sharma HS, Feng L, Chen L, Huang H, Tian ZR, Nozari A, Muresanu DF, Lafuente JV, Castellani RJ, Wiklund L, Sharma A. · 2026 · PMID 42143192

  87. 208.

    Doppler E, Rockenstein E, Ubhi K, Inglis C, Mante M, Adame A, Crews L, Hitzl M, Moessler H, Masliah E. · 2026 · PMID 41874695

  88. 209.

    Shchulkin AV, Chernykh IV, Abalenikhina YV, Gatsanoga MV, Kochetkova DL, Kruzhalov NA, Krestinina EV, Yakusheva EN. · 2026 · PMID 41782540

    <h4>Objective</h4>To compare the effects of Mexidol, Cerebrolysin, and Cortexin on the levels of brain-derived neurotrophic factor (BDNF), tumor necrosis factor-alpha (TNF<i>α</i>), and apoptosis markers in the rat brain following middle cerebral artery (MCA) occlusion-reperfusion.<h4>Material and methods</h4>The study was performed on male Wistar rats. Right MCA occlusion-reperfusion was modeled using the method of J. Koizumi (1986). The occlusion duration was 60 minutes (1 hour). At the onset…

  89. 210.

    Schlager P, Grgac I, Herzer G, Trimmel H. · 2025 · PMID 41409218

    <h4>Introduction</h4>Severe traumatic brain injury (sTBI) remains a major cause of long-term disability and mortality worldwide. Beyond the initial mechanical damage, a cascade of secondary injuries involving neuroinflammation, oxidative stress, and excitotoxicity exacerbates neural dysfunction. Neuroprotective agents such as citicoline and Cerebrolysin have shown promise in addressing these complex mechanisms and supporting recovery. This study aimed to evaluate whether a combination therapy of…

  90. 211.

    Ozkizilcik A, Sharma A, Muresanu DF, Lafuente JV, Tian ZR, Patnaik R, Mössler H, Sharma HS. · 2026 · PMID 41920231

  91. 212.

    Boontoterm P, Sakoolnamarka S, Urasyanandana K. · 2026 · PMID 42110924

    <h4>Objectives</h4>Moderate traumatic brain injury (TBI) with nonoperative intracerebral hemorrhage (ICH) presents a significant challenge in neurorehabilitation, often lacking targeted pharmacological interventions. Cerebrolysin, a neuropeptide compound with proposed neurotrophic and neuroprotective properties, may support recovery in this population. This study aimed to evaluate the clinical efficacy and safety of Cerebrolysin in adults with moderate TBI and nonoperative ICH over a 6-month per…

  92. 213.

    Ubhi K, Rockenstein E, Doppler E, Mante M, Adame A, Patrick C, Trejo M, Crews L, Paulino A, Moessler H, Masliah E. · 2026 · PMID 41817815

  93. 214.

    González JDSR, Tapia A. · 2025 · PMID 41532044

    Multimodal treatment of patients with a brain tumor primarily involves microsurgical excision, ideally radical, or at least subtotal resection. Tumors in deep or inaccessible locations may require biopsy followed by adjuvant therapy with chemotherapy, radiotherapy, or radiosurgery. Beyond controlling tumor growth, preserving neurological function and promoting brain plasticity are essential goals. Persistent inflammation and intracranial hypertension can trigger secondary injury through edema, e…

  94. 215.

    Karimian A, Abdolmaleki A, Asadi A, Zahri S, Ghanimi HA. · 2025 · PMID 41835059

    <h4>Purpose</h4>The research investigated the neuroprotective properties of Cerebrolysin regarding functional recovery, axonal regeneration, and macrophage polarization in a rat model of acute sciatic nerve damage.<h4>Methods</h4>The research included 72 male Wistar rats, categorized into six groups: sham control, crush injury, vehicle-treated crush damage, and two groups receiving Cerebrolysin treatment for crush injury. The assessment of functional recovery was conducted with the sciatic funct…

  95. 216.

    Kobayashi A, Rutkowska K, Gocyla-Dudar K, Chelstowska B, Pozarowszczyk N, Karlinski M. · 2025 · PMID 41180520

    <h4>Background</h4>Intracerebral hemorrhage (ICH) accounts for 15% of strokes with high mortality and limited treatment options. Cerebrolysin, a neuropeptide preparation with multimodal neuroprotective properties, has shown promise in acute ischemic stroke but remains inadequately studied in ICH.<h4>Methods</h4>CLINCH is an investigator led, academic driven multicenter, prospective, randomized, open-label, blinded endpoint (PROBE) phase IV pilot study evaluating cerebrolysin in primary lobar ICH…

  96. 217.

    Alexandrova EG, Abakumova TR, Ziganshina LE. · 2026 · PMID 41467376

    ObjectiveTo analyse regulatory positions and drug policies of the Commonwealth of Independent States (CIS), compared to those of the EU, UK, USA i of the nootropics, used in Russia for Alzheimer's disease.MethodsWe searched E-library to reveal the list of nootropics used and studied in Russia for Alzheimer's disease. We assessed official pharmaceutical registries of nine countries for registration status of identified nootropics, 7 National Essential Medicines Lists (EML), and four clinical prac…

  97. 218.

    Lee YS, Seo J, Yim SH. · 2025 · PMID 41178897

    Herpes simplex encephalitis (HSE) is a severe central nervous system (CNS) infection associated with cognitive decline, psychotic symptoms, and epilepsy. Despite aggressive antiviral and corticosteroid treatments, post-HSE complications remain challenging to manage. We report a case of a 33-year-old female patient with post-HSE neuropsychiatric symptoms who showed significant improvement following Cerebrolysin treatment. The patient was treated with acyclovir and dexamethasone in the acute phase…

  98. 219.

    Kandasamy G, Arumugam V, Orayj K, Alshahrani AM, Alanazi TS, Hmlan A, Venugopal JP. · 2025 · PMID 41010922

    <i>Background and Objectives:</i> Acute ischemic stroke is a major cause of disability and mortality. Cerebrolysin, a neuropeptide with neuroprotective and neurotrophic properties, may enhance post-stroke recovery. This study evaluated the impact of adding Cerebrolysin to standard therapy on clinical outcomes in patients with acute ischemic stroke. <i>Materials and Methods:</i> This non-randomized prospective observational study included 143 adults with acute ischemic stroke at Kovai Medical Cen…

  99. 220.

    Hosseini L, Abolhasanpour N, Seyedaghamiri F, Hassanzadeh P, Shahabi P, Mafikandi V, Kalejahi P, Rajabi M, Shokri Z, Fakhari A. · 2025 · PMID 41204270

    Schizophrenia is known as a complex and devastating mental disorder due to its profound impact on individuals, families, and society. Emerging evidence proposes that mitochondria play a central role in schizophrenia. Here, we investigated whether cerebrolysin (CBL) can alleviate anxiety-like behaviors and cognitive deficits through a mechanism involving the CREB/PGC-1α pathway. In this study, 30 male BALB/c mice were randomly assigned to three different groups: Control, Ketamine, and Ketamine +…

  100. 221.

    Rockenstein E, Ubhi K, Trejo M, Mante M, Patrick C, Adame A, Novak P, Jech M, Doppler E, Moessler H, Masliah E. · 2025 · PMID 41382024

  101. 222.

    Akbari-Gharalari N, Aliyari-Serej Z, Ghahremani-Nasab M, Zangbar HS, Yahyavi Y, Nezhadshahmohammad F, Ebrahimi-Kalan A. · 2026 · PMID 40470992

    <h4>Context/objective</h4>Spinal cord injury (SCI) is a severe condition characterized by neuronal apoptosis and inflammation, with limited therapeutic options. This study aimed to assess the effects of platelet-rich plasma (PRP)-derived exosomes (Exo), Cerebrolysin (CBL), and Cerebrolysin-loaded exosomes (CLE) on inflammation, apoptosis, tissue organization, and motor function recovery in a mouse model of compression SCI.<h4>Design</h4>An experimental study using a mouse model of SCI, investiga…

  102. 223.

    Livinț-Popa L, Chelaru VF, Chertic-Dăbală D, Chira D, Verișezan-Roșu O, Dăbală V, Drăghici N, Maer E, Strilciuc Ş, Mureșanu D. · 2025 · PMID 41395158

    <h4>Introduction</h4>Traumatic brain injury (TBI) is a leading cause of disability and death. Both repetitive transcranial magnetic stimulation (rTMS) and Cerebrolysin (CRB) are promising therapies regulating neural plasticity. This study aimed to assess the changes in resting-state brain activity following CRB, rTMS, or combined CRB-rTMS therapy.<h4>Methods</h4>This secondary analysis of the CAPTAIN-rTMS trial analyzed eyes-closed segments from EEG recordings at 30 days (baseline) and 180 days…

  103. 224.

    Kojder K, Gąssowska-Dobrowolska M, Żwierełło W, Kłos P, Piotrowska K, Wszołek A, Maruszewska A, Gutowska I, Chlubek D, Baranowska-Bosiacka I. · 2025 · PMID 40362194

    Acute brain injury includes different pathologies: stroke, traumatic injury, subarachnoidale haemorhhage. In the pathophysiology of acute brain injury, secondary injury with hyperactivation of glia plays a crucial role. Activated glial cells induce prolonged inflammation that impacts the recovery and further cognitive functions of patients. In our study, we have examined the neuroprotective impact of exogenous neuropeptides-Cerebrolysin on astrocytes under different conditions. In a model that s…

  104. 225.

    Rockenstein E, Ubhi K, Mante M, Florio J, Adame A, Winter S, Brandstaetter H, Meier D, Masliah E. · 2025 · PMID 40065222

  105. 226.

    ElBassiouny A, Shehata MSA, Zaki AS, Bedros RY, El-Sudany AH, Nasser AA. · 2025 · PMID 40027163

    <h4>Introduction</h4>Endovascular recanalization therapy has demonstrated considerable efficacy in the treatment of acute ischemic stroke (AIS). However, not all patients appear to benefit on the long term from this therapy. No studies have assessed the role of Cerebrolysin following mechanical thrombectomy (MT). The present study was conducted to evaluate the safety and efficacy of Cerebrolysin as add-on treatment to MT in patients with cardioembolic AIS.<h4>Methods</h4>This study evaluated 150…

  106. 227.

    Pantoni L, Pikija S, Nguyen TV, Brainin M. · 2026 · PMID 42058538

    Post-stroke cognitive impairment (PSCI) affects up to one-third of stroke survivors and is a major contributor to long-term disability and reduced quality of life. Its heterogeneous phenotype reflects the interplay of acute cerebrovascular injury with chronic vascular pathology, inflammation, blood-brain barrier dysfunction, and, in many patients, coexisting neurodegeneration. Clinical manifestations vary according to lesion location and most commonly involve executive and attentional deficits,…

  107. 228.

    Cárdenas-Bedoya J, Torres-Mendoza BM, Martínez-Torres NI. · 2025 · PMID 40123021

    Several psychopathologies may be triggered, among other factors, by stress or trauma in childhood. The maternal deprivation model (MD) replicates some of the core factors that may induce the onset of different psychopathologies like structural and plasticity defects. Among other brain regions, the amygdala is susceptible to stress and trauma and plays a key role in integrating social behavior. Several molecules, such as Cerebrolysin<sup>®</sup> (CBL), have been used to treat different symptoms b…

  108. 229.

    Kalinin MN, Khasanova DR. · 2025 · PMID 40123141

    <h4>Objective</h4>To evaluate the effect of Cerebrolysin on hazard dynamics of hemorrhagic transformation (HT) and identify optimal anticoagulation therapy (AT) resumption timing in stroke patients, stratified by the Hemorrhagic Transformation Index (HTI).<h4>Material and methods</h4>A post hoc survival analysis of the CEREHETIS trial (ISRCTN87656744) included patients with middle cerebral artery infarctions. The intervention group (IG, <i>n</i>=91) received Cerebrolysin with intravenous thrombo…

  109. 230.

    Kalinin MN, Khasanova DR. · 2025 · PMID 40577185

    <h4>Objective</h4>To evaluate the effects of Cerebrolysin on brain microstructural integrity and blood-brain barrier (BBB) permeability, as well as their longitudinal changes, using diffusion tensor imaging (DTI) and perfusion computed tomography (PCT) in patients with acute ischemic stroke (AIS).<h4>Material and methods</h4>This analysis included patients from the multimodal brain imaging subgroup of the prospective CEREHETIS trial (ISRCTN87656744) with AIS in the middle cerebral artery territo…

  110. 231.

    Ghavipanjeh G, Taeb S, Farzin MA, Farhood B, Najafi M, Ardjmand A. · 2025 · PMID 38676482

    <h4>Aim</h4>The aim of this study is to evaluate radioprotective effects of Cerebrolysin (CBL) in rats' brain tissues after local irradiation.<h4>Background</h4>CBL has demonstrated antioxidant, anti-inflammatory, and tissue repair properties. In this study, the radioprotective effects of CBL in the brain tissues of rats after Irradiation (IR) (50 mg/ kg) were evaluated.<h4>Objective</h4>The levels of different oxidative stress markers, including malondialdehyde (MDA), nitric oxide (NO), glutath…

  111. 232.

    Ede O, Cheung JPY. · 2025 · PMID 40191170

    Degenerative cervical myelopathy (DCM) is the most common cause of non-traumatic spinal cord dysfunction in adults worldwide. Conservative treatments, such as physical therapy, activity modification, cervical traction, and the use of cervical collars, have been employed primarily for symptomatic relief in mild cases or for patients deemed unfit for surgery. Advances in our understanding of the molecular pathways involved in neuroinflammation and neuronal injury in DCM have spurred the developmen…

  112. 233.

    Espinoza I, Gómez-Villalobos MJ, Aguilar-Hernández L, Flores G, Morales-Medina JC. · 2025 · PMID 39826813

    Hypertension, if untreated, can disrupt the blood-brain-barrier (BBB) and reduce cerebral flow in the central nervous system (CNS) inducing hippocampal atrophy, potentially leading to cognitive deficits and vascular dementia. Spontaneous hypertensive rats (SHR) demonstrated neuroplastic alterations in the hippocampus, hyperlocomotion and memory deficits in males. Cerebrolysin (CBL), a neuropeptide preparation, induces synaptic and neuronal plasticity in various populations of neurons and repairs…

  113. 234.
  114. 235.

    Mangalagiu AG, Petrescu BM, Riga S, Vasiliu O. · 2025 · PMID 41562827

    Mild cognitive impairment (MCI) is a nosological entity that requires special attention from a therapeutic perspective, because annual conversion rates to dementia of 5-15% in these cases are considered typical. This narrative review aimed to identify available data supporting the efficacy and tolerability of various pharmacological therapeutic interventions by searching PubMed/MEDLINE, the Cochrane Database of Systematic Reviews, and the Web of Science (WoS) Core Collection for primary and seco…

  115. 236.

    Wesley MJ, Gundala Raja H, Shahid MS, Akbar A, Jeyakumar D, Veluchamy E, Sivakumar M, Tahir F, Jiménez Royg D, Pant R, Rehman A. · 2025 · PMID 40842809

    This systematic review evaluates the effectiveness and safety of adjunctive neuroprotective therapies administered in combination with reperfusion treatments, either intravenous (IV) thrombolysis, mechanical thrombectomy, or both, in adult patients with acute ischemic stroke (AIS). Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive search of four major databases was conducted with filters applied to include English-language randomize…

  116. 237.

    Marchenko SV, Hil IH, Hil UV, Smolskaya NY. · 2025 · PMID 40879237

    We present a clinical case of cancer-associated ischemic stroke in a 70-year-old patient with metastatic sigmoid colon cancer. The patient was admitted to the hospital in the hyperacute stage of ischemic stroke due to thrombosis of the left middle cerebral artery, complicated by severe global aphasia and right-sided hemiplegia (NIHSS - 20). Despite the high risk of hemorrhagic complications associated with underlying malignancy, systemic thrombolysis with alteplase was successfully administered;…

  117. 238.

    Aguilar-Hernández L, Flores-Gómez GD, Nacher J, Morales-Medina JC, Flores G. · 2025 · PMID 41460391

    Aging is associated with progressive synaptic deterioration and cognitive decline; however, therapeutic strategies capable of restoring both structural and functional deficits remain limited. This study evaluated the effects of aging on dendritic spine dynamics and recognition memory across multiple brain regions, and evaluated whether chronic treatment with cerebrolysin (CBL) could ameliorate age-related alterations (3, 6, 12 and 18 months of age). We additionally assessed the effects of CBL on…

  118. 239.

    Jeon H, Kim DY. · 2024 · PMID 39113920

    Cerebrolysin concentrate is a medication whose main active ingredient is brain-derived neurotrophic factor. It has been reported to help in the restoration of cognitive function and overall physical function after brain injuries. We present the case of a 72-year-old man with severe oral apraxia due to a left middle cerebral artery ischemic stroke involving the left insular cortex. He was being tube fed due to severe oral apraxia with cognitive decline that made it difficult for him to even imita…

  119. 240.

    Stadnik A, Jezierska M, Płotek W, Siwicka D, Mlak R, Dąbrowski W. · 2025 · PMID 40350671

    BACKGROUND The occurrence of delirium in the first days after cardiac surgery is associated with a worse prognosis. We studied the effect of cerebrolysin (CBL) given to patients undergoing elective coronary artery bypass grafting surgery (CABG) under extracorporeal circulation, on the postoperative results in the Montreal Cognitive Assessment score (MoCA) results, and the rate of delirium detected by using the Confusion Assessment Method (CAM). MATERIAL AND METHODS Adult patients undergoing elec…

  120. 241.
  121. 242.

    Ziąbska H, Kobayashi A, Karliński M · Case reports in neurological medicine · 2026 · PMID 42666484

    Despite high recanalization rates with mechanical thrombectomy (MT), large-vessel occlusion stroke results in death or dependency in over half of patients. Cerebrolysin, a multimodal neuropeptide preparation, may attenuate ischemia-reperfusion injury and support early neurorehabilitation. We report a 88-year-old woman with moderate prestroke disability who presented 2 h after the onset of right hemiparesis and aphasia due to M2 occlusion of the left middle cerebral artery. She received intraveno…

  122. 243.

    Chiu HC, Yangchen Y, Pengiran Tengah DSNA, Chum NN, et al. · Cerebrovascular diseases extra · 2026 · PMID 42525569

    Our recently-published systematic-search-and-review identified eight registered treatments with level A or B-R evidence of improving neuro-recovery after a stroke. In this study, we aimed to assess their availability, usage, and recommendation in national guidelines in different Asian countries or regions. We conducted a survey on availability, estimated usage in stroke patients, inclusion in local stroke guidelines, and if they believed more clinical trials were necessary for nimodipine, edarav…

  123. 244.

    Teng H, Li C, Wang M, Zhang J, et al. · Cells · 2026 · PMID 42193943

    Cerebrolysin has a salutary effect on impaired cerebral endothelial cell (CEC) permeability. Using an in vitro endothelial permeability assay, the present study tested the hypothesis that exosomes released by Cerebrolysin-treated CECs (Cerebro-Exos) have a robust therapeutic effect on dysfunctional CECs. Stoichiometric analysis showed marked differences in cargo profiles between Cerebro-Exos and exosomes derived from CECs without Cerebrolysin treatment (Naïve-Exos), in which Cerebro-Exos were hi…

Preprints (not yet peer-reviewed)

5
  1. 245.

    Kalinin MN, Khasanova DR. · 2025

    <title>Abstract</title> <p> <bold>Background</bold> The timing of anticoagulation resumption after ischemic stroke remains uncertain, especially in patients at high risk of hemorrhagic transformation (HT). Although Cerebrolysin reduces HT incidence, its impact on dynamic risk evolution and the safe therapeutic window is unknown. <bold>Methods</bold> This <italic>post-hoc</italic> survival analysis of the CEREHETIS trial (ISRCTN87656744) included 238 patients with middle cerebral artery infarctio…

  2. 246.

    Baran H, Kronsteiner C. · 2025

    Kynurenic acid (KYNA) is a byproduct of the kynurenine pathway, which breaks down the amino acid tryptophan. KYNA acts as an antagonist of glutamate ionotropic excitatory amino acid (EAA) receptors and α7 nicotinic acetylcholine receptors (nAChRs). There is evidence that KYNA plays a significant role in various pathological conditions and the ageing process. It has also been suggested that KYNA contributes to memory impairment. This study investigated the impact of L-kynurenine, D-cycloserine, a…

  3. 247.

    Chen S, Zhuang Y, Li R, Chang C, Zheng G. · 2025

    <title>Abstract</title> <p>Introduction: Sensorineural hearing loss (SNHL) is a common sensory disorder characterized by auditory nerve damage and cochlear dysfunction, often driven by oxidative stress, excitotoxicity, and neuroinflammation. Neuroprotective agents such as Cerebrolysin, Citicoline, Flunarizine, and Mecobalamin have demonstrated efficacy in addressing these mechanisms by reducing oxidative damage, modulating calcium overload, and promoting neuronal repair. Despite their therapeuti…

  4. 248.

    Staszewski J, Dębiec A, Strilciuc S, Gniadek-Olejniczak K, Piusinska-Macoch R, Balo D, Harston G, Stępień A, Brzozowski K, Zięcina P, Narloch J, Wierzbicki M, Piasecki P. · 2025

    <h4>Background and Aims</h4> This study hypothesized that Cerebrolysin, a multimodal neuroprotective agent, enhances the efficacy and safety of mechanical thrombectomy (MT) in both acute ischemic stroke (AIS) and recovery stroke phases in selected patients with good collateral status (CTA-CS 2-3) and effective recanalization (mTICI 2b-3). <h4>Methods</h4> A single-center, prospective, open-label, single-arm study with blinded outcome assessment of 50 consecutive patients with moderate-to-severe…

  5. 249.

    Kalinin MN, Khasanova DR. · 2024

    <title>Abstract</title> <p> Background Evidence supports Cerebrolysin’s efficacy in reducing hemorrhagic transformation (HT), but its impact on the timing of resuming anticoagulation therapy in stroke patients remains unclear. Methods A <italic>post hoc</italic> survival analysis of the CEREHETIS trial (ISRCTN87656744) was conducted. Patients with middle cerebral artery infarction ( <italic>n</italic> = 238) were categorized into low-risk (HTI = 0) and high-risk (HTI > 0) groups based on HTI sco…

Case Reports

5
  1. 250.

    Trimmel H, Tauber W, Zikeli M · Case reports in neurological medicine · 2024 · PMID 39055722

    In this case report, we describe a well-documented, severe anaphylactic reaction after intravenous administration of cerebrolysin, a neurotrophic agent derived from highly purified porcine brain tissue, consisting of peptides and free amino acids. Cerebrolysin has been in use for decades, in various neurological diseases, but especially stroke and traumatic brain injury, with the aim of enhancing cognitive performance. After administration of cerebrolysin to an 85-year-old male patient suffering…

  2. 251.

    Eichel R, Mausbach S, Teicher M, Bornstein NM · Journal of medicine and life · 2026 · PMID 42891269

    Acute ischemic stroke patients may demonstrate persistent tissue-level hypoperfusion despite successful angiographic recanalization after mechanical thrombectomy. We report a 57-year-old man with wake-up stroke due to tandem occlusion of the right internal carotid artery and M1 middle cerebral artery who presented with left hemiparesis, neglect, and dysarthria (National Institutes of Health Stroke Scale, NIHSS, score 7). Computed tomography perfusion showed salvageable penumbral tissue, and he u…

  3. 252.

    Choi J · Journal of medicine and life · 2026 · PMID 42751610

    Aphasia is a common and disabling consequence of dominant-hemisphere brain injury, and the pharmacological options after traumatic intracranial hemorrhage are limited. A 69-year-old man developed severe aphasia after traumatic intracranial hemorrhage. On day 7 after traumatic brain injury (TBI), he was transferred for inpatient rehabilitation, where the Korean version of the Western Aphasia Battery (K-WAB) showed marked language impairment, with an Aphasia Quotient (AQ) of 66.2 (scale 0-100; hig…

  4. 253.

    Roje Bedeković M, Ivona J, Bosnar Puretić M · Journal of medicine and life · 2026 · PMID 42602665

    Basilar artery occlusion (BAO) is an uncommon yet devastating cause of posterior circulation stroke, frequently resulting in severe disability or death despite successful reperfusion. We describe a 67-year-old woman with multiple vascular risk factors who presented with acute BAO and was treated with intravenous thrombolysis followed by successful mechanical thrombectomy (Thrombolysis in Cerebral Infarction [TICI] grade 3), with adjunctive Cerebrolysin therapy administered subsequently. Rapid ne…

  5. 254.

    Romano M · Journal of medicine and life · 2026 · PMID 42602663

    Post-stroke aphasia is a debilitating condition affecting approximately one-third of stroke survivors, profoundly impairing communication, social participation, and quality of life. While speech-language therapy (SLT) remains the standard of care, pharmacological agents such as Cerebrolysin may enhance recovery through neuroprotection and neuroplasticity. We report the case of a 38-year-old female lawyer who developed acute Wernicke's aphasia and right-sided hemiparesis following an ischemic str…

Curated sources on file

15
  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.
  10. 10.
  11. 11.
  12. 12.
  13. 13.
  14. 14.
  15. 15.

Continue reading